

Putting p53 in Context

Cell

170, 1062-1078

DOI: [10.1016/j.cell.2017.08.028](https://doi.org/10.1016/j.cell.2017.08.028)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Ets2 anchors the prometastatic function of mutant p53 in osteosarcoma. <i>Genes and Development</i> , 2017, 31, 1823-1824.	2.7	13
2	Elevated p53 Activities Restrict Differentiation Potential of MicroRNA-Deficient Pluripotent Stem Cells. <i>Stem Cell Reports</i> , 2017, 9, 1604-1617.	2.3	12
3	Induction of the p53 Tumor Suppressor in Cancer Cells through Inhibition of Cap-Dependent Translation. <i>Molecular and Cellular Biology</i> , 2018, 38, .	1.1	11
4	The tango of ROS and p53 in tissue stem cells. <i>Cell Death and Differentiation</i> , 2018, 25, 639-641.	5.0	59
5	Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition. <i>Cancer Research</i> , 2018, 78, 2721-2731.	0.4	37
6	Salinomycin derivatives exhibit activity against primary acute lymphoblastic leukemia (ALL) cells in vitro. <i>Biomedicine and Pharmacotherapy</i> , 2018, 99, 384-390.	2.5	23
7	Early onset sporadic colorectal cancer: Worrisome trends and oncogenic features. <i>Digestive and Liver Disease</i> , 2018, 50, 521-532.	0.4	65
8	APR-246 reactivates mutant p53 by targeting cysteines 124 and 277. <i>Cell Death and Disease</i> , 2018, 9, 439.	2.7	182
9	Design, in silico prioritization and biological profiling of apoptosis-inducing lactams amenable by the Castagnoli-Cushman reaction. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 2651-2673.	1.4	10
10	Targeting HAUSP in both p53 wildtype and p53-mutant tumors. <i>Cell Cycle</i> , 2018, 17, 823-828.	1.3	17
11	Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas. <i>Cell Reports</i> , 2018, 23, 239-254.e6.	2.9	801
12	PMN inhibits colorectal cancer cells through inducing mitotic arrest and p53-dependent apoptosis via the inhibition of tubulin polymerization. <i>Biochemical and Biophysical Research Communications</i> , 2018, 499, 927-933.	1.0	9
13	Clonal Hematopoiesis and Evolution to Hematopoietic Malignancies. <i>Cell Stem Cell</i> , 2018, 22, 157-170.	5.2	345
14	Established, emerging and elusive molecular targets in the treatment of lung cancer. <i>Journal of Pathology</i> , 2018, 244, 565-577.	2.1	15
15	Profile of Scott W. Lowe. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 630-632.	3.3	6
16	Treatment of Uterine Sarcoma with rAd-p53 (Gencicine) Followed by Chemotherapy: Clinical Study of TP53 Gene Therapy. <i>Human Gene Therapy</i> , 2018, 29, 242-250.	1.4	21
17	Targeting the Prion-like Aggregation of Mutant p53 to Combat Cancer. <i>Accounts of Chemical Research</i> , 2018, 51, 181-190.	7.6	88
18	p53 is required for female germline stem cell maintenance in P-element hybrid dysgenesis. <i>Developmental Biology</i> , 2018, 434, 215-220.	0.9	24

#	ARTICLE	IF	CITATIONS
19	Hematopoietic insults damage bone marrow niche by activating p53 in vascular endothelial cells. <i>Experimental Hematology</i> , 2018, 63, 41-51.e1.	0.2	14
20	Germline Duplication of SNORA18L5 Increases Risk for HBV-related Hepatocellular Carcinoma by Altering Localization of Ribosomal Proteins and Decreasing Levels of p53. <i>Gastroenterology</i> , 2018, 155, 542-556.	0.6	75
21	Cancer-Cell-Intrinsic Mechanisms Shaping the Tumor Immune Landscape. <i>Immunity</i> , 2018, 48, 399-416.	6.6	442
22	Cell cycle and apoptosis regulator 2 at the interface between DNA damage response and cell physiology. <i>Mutation Research - Reviews in Mutation Research</i> , 2018, 776, 1-9.	2.4	32
23	Mutant p53 in breast cancer: potential as a therapeutic target and biomarker. <i>Breast Cancer Research and Treatment</i> , 2018, 170, 213-219.	1.1	144
24	Functional crosstalk among oxidative stress and O-GlcNAc signaling pathways. <i>Glycobiology</i> , 2018, 28, 556-564.	1.3	35
25	Computational simulations and experimental validation of structure- physicochemical properties of pristine and functionalized graphene: Implications for adverse effects on p53 mediated DNA damage response. <i>International Journal of Biological Macromolecules</i> , 2018, 110, 540-549.	3.6	7
26	TERT structural rearrangements in metastatic pheochromocytomas. <i>Endocrine-Related Cancer</i> , 2018, 25, 1-9.	1.6	45
27	Targeting mutant p53 for efficient cancer therapy. <i>Nature Reviews Cancer</i> , 2018, 18, 89-102.	12.8	655
28	MEF2 plays a significant role in the tumor inhibitory mechanism of encapsulated RENCA cells via EGF receptor signaling in target tumor cells. <i>BMC Cancer</i> , 2018, 18, 1217.	1.1	8
29	Profiles of genomic alterations in primary esophageal follicular dendritic cell sarcoma. <i>Medicine (United States)</i> , 2018, 97, e13413.	0.4	10
30	tp53 deficiency causes a wide tumor spectrum and increases embryonal rhabdomyosarcoma metastasis in zebrafish. <i>ELife</i> , 2018, 7, .	2.8	51
31	Oncogenic Metabolism Acts as a Prerequisite Step for Induction of Cancer Metastasis and Cancer Stem Cell Phenotype. <i>Oxidative Medicine and Cellular Longevity</i> , 2018, 2018, 1-28.	1.9	48
32	Strategies targeting cellular senescence. <i>Journal of Clinical Investigation</i> , 2018, 128, 1247-1254.	3.9	153
33	Recent Trends in Covalent and Metal Organic Frameworks for Biomedical Applications. <i>Nanomaterials</i> , 2018, 8, 916.	1.9	69
34	A 15-lncRNA signature predicts survival and functions as a ceRNA in patients with colorectal cancer. <i>Cancer Management and Research</i> , 2018, Volume 10, 5799-5806.	0.9	56
35	Oxidative Stress in Cells with Extra Centrosomes Drives Non-Cell-Autonomous Invasion. <i>Developmental Cell</i> , 2018, 47, 409-424.e9.	3.1	100
36	A Transcriptional Regulatory Network Model Reveals miR-34a as a Potential Regulator of Proliferation in Cancer Cell Lines. , 2018, , .		0

#	ARTICLE	IF	CITATIONS
37	Expression of mitochondrial dysfunction-related genes and pathways in paclitaxel-induced peripheral neuropathy in breast cancer survivors. <i>Molecular Pain</i> , 2018, 14, 174480691881646.	1.0	34
38	The Role of RNA Editing in Cancer Development and Metabolic Disorders. <i>Frontiers in Endocrinology</i> , 2018, 9, 762.	1.5	70
39	Autophagy and Its Role in Protein Secretion: Implications for Cancer Therapy. <i>Mediators of Inflammation</i> , 2018, 2018, 1-17.	1.4	34
40	Loss of Tumor Suppressor Gene Function in Human Cancer: An Overview. <i>Cellular Physiology and Biochemistry</i> , 2018, 51, 2647-2693.	1.1	206
41	p53-mediated adaptation to serine starvation is retained by a common tumour-derived mutant. <i>Cancer & Metabolism</i> , 2018, 6, 18.	2.4	36
42	Curaxin CBL0137 Exerts Anticancer Activity via Diverse Mechanisms. <i>Frontiers in Oncology</i> , 2018, 8, 598.	1.3	24
43	SOG1 activator and MYB3R repressors regulate a complex DNA damage network in <i>Arabidopsis</i> . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E12453-E12462.	3.3	115
44	Epithelial-specific histone modification of the miR-96/182 locus targeting AMAP1 mRNA predisposes p53 to suppress cell invasion in epithelial cells. <i>Cell Communication and Signaling</i> , 2018, 16, 94.	2.7	8
45	A Well-Controlled BioID Design for Endogenous Bait Proteins. <i>Journal of Proteome Research</i> , 2019, 18, 95-106.	1.8	13
46	Epigenetically distinct sister chromatids and asymmetric generation of tumor initiating cells. <i>Cell Cycle</i> , 2018, 17, 2221-2229.	1.3	1
47	Science in Focus: Genomic Instability and its Implications for Clinical Cancer Care. <i>Clinical Oncology</i> , 2018, 30, 751-755.	0.6	8
48	Highly efficient genome editing via CRISPR-Cas9 in human pluripotent stem cells is achieved by transient BCL-XL overexpression. <i>Nucleic Acids Research</i> , 2018, 46, 10195-10215.	6.5	93
49	Metabolic Plasticity of Tumor Cell Mitochondria. <i>Frontiers in Oncology</i> , 2018, 8, 333.	1.3	74
50	NAD ⁺ Reduction and ROS-Mediated AKT/FOXO1 and AKT/P53 Pathways Are Involved in Growth Promotion and Cytotoxicity of Cyadox. <i>Chemical Research in Toxicology</i> , 2018, 31, 1219-1229.	1.7	13
51	Photoactivation of MDM2 Inhibitors: Controlling Protein-Protein Interaction with Light. <i>Journal of the American Chemical Society</i> , 2018, 140, 13136-13141.	6.6	35
52	Breast cancer survival predicted by TP53 mutation status differs markedly depending on treatment. <i>Breast Cancer Research</i> , 2018, 20, 115.	2.2	63
53	Association analysis using somatic mutations. <i>PLoS Genetics</i> , 2018, 14, e1007746.	1.5	8
54	Prostate cancer aggressiveness and age: Impact of p53, BCL-2 and microvessel density. <i>Journal of Investigative Medicine</i> , 2018, 66, 1142-1146.	0.7	9

#	ARTICLE	IF	CITATIONS
55	Consensus report of the 8 and 9th Weinman Symposia on Gene x Environment Interaction in carcinogenesis: novel opportunities for precision medicine. <i>Cell Death and Differentiation</i> , 2018, 25, 1885-1904.	5.0	31
56	Facilitated Diffusion Mechanisms in DNA Base Excision Repair and Transcriptional Activation. <i>Chemical Reviews</i> , 2018, 118, 11298-11323.	23.0	50
57	Opposite Carcinogenic Effects of Circadian Clock Gene BMAL1. <i>Scientific Reports</i> , 2018, 8, 16023.	1.6	46
58	p53 mutants cooperate with HIF-1 in transcriptional regulation of extracellular matrix components to promote tumor progression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E10869-E10878.	3.3	102
59	Transposons, p53 and Genome Security. <i>Trends in Genetics</i> , 2018, 34, 846-855.	2.9	33
60	Clonal Hematopoiesis and Its Impact on Cardiovascular Disease. <i>Circulation Journal</i> , 2018, 83, 2-11.	0.7	42
61	p53 Functions in Adipose Tissue Metabolism and Homeostasis. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2622.	1.8	68
62	The p53 Pathway in Glioblastoma. <i>Cancers</i> , 2018, 10, 297.	1.7	232
63	2D DIGE proteomic analysis reveals fasting-induced protein remodeling through organ-specific transcription factor(s) in mice. <i>FEBS Open Bio</i> , 2018, 8, 1524-1543.	1.0	8
64	Re-purposing Chloroquine for Glioblastoma: Potential Merits and Confounding Variables. <i>Frontiers in Oncology</i> , 2018, 8, 335.	1.3	59
65	p53 Isoforms and Their Implications in Cancer. <i>Cancers</i> , 2018, 10, 288.	1.7	87
66	TRMP, a p53-inducible long noncoding RNA, regulates G1/S cell cycle progression by modulating IRES-dependent p27 translation. <i>Cell Death and Disease</i> , 2018, 9, 886.	2.7	32
67	Advanced forms of MPNs are accompanied by chromosomal abnormalities that lead to dysregulation of TP53. <i>Blood Advances</i> , 2018, 2, 3581-3589.	2.5	49
68	Regulation and function of p53: A perspective from Drosophila studies. <i>Mechanisms of Development</i> , 2018, 154, 82-90.	1.7	53
69	ActiveDriverDB: human disease mutations and genome variation in post-translational modification sites of proteins. <i>Nucleic Acids Research</i> , 2018, 46, D901-D910.	6.5	82
70	p53 Mediates Vast Gene Expression Changes That Contribute to Poor Chemotherapeutic Response in a Mouse Model of Breast Cancer. <i>Translational Oncology</i> , 2018, 11, 930-940.	1.7	13
71	p53 is required for brain growth but is dispensable for resistance to nutrient restriction during Drosophila larval development. <i>PLoS ONE</i> , 2018, 13, e0194344.	1.1	6
72	Detection of a novel, primate-specific "kill switch" tumor suppression mechanism that may fundamentally control cancer risk in humans: an unexpected twist in the basic biology of TP53. <i>Endocrine-Related Cancer</i> , 2018, 25, R497-R517.	1.6	6

#	ARTICLE	IF	CITATIONS
73	Mitotic polarization of transcription factors during asymmetric division establishes fate of forming cancer cells. <i>Nature Communications</i> , 2018, 9, 2424.	5.8	18
74	Deregulation of Retroelements as an Emerging Therapeutic Opportunity in Cancer. <i>Trends in Cancer</i> , 2018, 4, 583-597.	3.8	53
75	Epigenetic Mechanisms Dictating Eradication of Cancer by Natural Killer Cells. <i>Trends in Cancer</i> , 2018, 4, 553-566.	3.8	22
76	P53/PUMA are potential targets that mediate the protection of brain-derived neurotrophic factor (BDNF)/TrkB from etoposide-induced cell death in neuroblastoma (NB). <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2018, 23, 408-419.	2.2	10
77	Immunogenomics Analysis Reveals that TP53 Mutations Inhibit Tumor Immunity in Gastric Cancer. <i>Translational Oncology</i> , 2018, 11, 1171-1187.	1.7	94
78	Ceramide Signaling and p53 Pathways. <i>Advances in Cancer Research</i> , 2018, 140, 191-215.	1.9	43
79	TNFAIP8 promotes the proliferation and cisplatin chemoresistance of non-small cell lung cancer through MDM2/p53 pathway. <i>Cell Communication and Signaling</i> , 2018, 16, 43.	2.7	61
80	Contribution of genotoxic anticancer treatments to the development of multiple primary tumours in the context of germline TP53 mutations. <i>European Journal of Cancer</i> , 2018, 101, 254-262.	1.3	32
81	Two Nucleolar Proteins, GDP1 and OLI2, Function As Ribosome Biogenesis Factors and Are Preferentially Involved in Promotion of Leaf Cell Proliferation without Strongly Affecting Leaf Adaxial-Abaxial Patterning in <i>Arabidopsis thaliana</i> . <i>Frontiers in Plant Science</i> , 2017, 8, 2240.	1.7	35
82	p53-Autophagy-Metastasis Link. <i>Cancers</i> , 2018, 10, 148.	1.7	34
83	Mouse Homolog of the Human TP53 R337H Mutation Reveals Its Role in Tumorigenesis. <i>Cancer Research</i> , 2018, 78, 5375-5383.	0.4	24
84	Transcriptional Repression of p53 by PAX3 Contributes to Gliomagenesis and Differentiation of Glioma Stem Cells. <i>Frontiers in Molecular Neuroscience</i> , 2018, 11, 187.	1.4	15
85	Translation Control by p53. <i>Cancers</i> , 2018, 10, 133.	1.7	18
86	Good Guy or Bad Guy? The Duality of Wild-Type p53 in Hormone-Dependent Breast Cancer Origin, Treatment, and Recurrence. <i>Cancers</i> , 2018, 10, 172.	1.7	10
87	Emerging Roles of p53 Family Members in Glucose Metabolism. <i>International Journal of Molecular Sciences</i> , 2018, 19, 776.	1.8	84
88	p53 as a Dichotomous Regulator of Liver Disease: The Dose Makes the Medicine. <i>International Journal of Molecular Sciences</i> , 2018, 19, 921.	1.8	47
89	CRISPR: Stressed about p53?. <i>Trends in Molecular Medicine</i> , 2018, 24, 731-733.	3.5	8
90	MDM2-TP53 Crossregulation: An Underestimated Target to Promote Loss of TP53 Function and Cell Survival. <i>Trends in Cancer</i> , 2018, 4, 602-605.	3.8	6

#	ARTICLE	IF	CITATIONS
91	How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance. <i>Drug Resistance Updates</i> , 2018, 38, 27-43.	6.5	91
92	The Guanylate Cyclase cGMP Signaling Axis Opposes Intestinal Epithelial Injury and Neoplasia. <i>Frontiers in Oncology</i> , 2018, 8, 299.	1.3	37
93	Inhibition of the glutaredoxin and thioredoxin systems and ribonucleotide reductase by mutant p53-targeting compound APR-246. <i>Scientific Reports</i> , 2018, 8, 12671.	1.6	53
94	Revealing a human p53 universe. <i>Nucleic Acids Research</i> , 2018, 46, 8153-8167.	6.5	75
95	The transcription and expression profile of p53 N236S mutant reveals new aspects of gain of function for mutant p53. <i>FEBS Letters</i> , 2018, 592, 3183-3197.	1.3	5
96	TP53. , 2018, , .		0
97	Mammalia: Proboscidea: Elephant Immune System. , 2018, , 863-883.		1
98	Altered p53 functionality in cancer-associated fibroblasts contributes to their cancer-supporting features. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 6410-6415.	3.3	81
99	Control of metabolism by p53 – Cancer and beyond. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2018, 1870, 32-42.	3.3	133
100	TSPYL2 is a novel regulator of SIRT1 and p300 activity in response to DNA damage. <i>Cell Death and Differentiation</i> , 2019, 26, 918-931.	5.0	38
101	Integrin β 4-Src-AKT signaling induces cellular senescence by counteracting apoptosis in irradiated tumor cells and tissues. <i>Cell Death and Differentiation</i> , 2019, 26, 245-259.	5.0	28
102	The tumor suppressor protein p53 and the ferroptosis network. <i>Free Radical Biology and Medicine</i> , 2019, 133, 162-168.	1.3	384
103	Varacin-1, a novel analog of varacin C, induces p53-independent apoptosis in cancer cells through ROS-mediated reduction of XIAP. <i>Acta Pharmacologica Sinica</i> , 2019, 40, 222-230.	2.8	3
104	Composite Adrenocortical Carcinoma and Neuroblastoma in an Infant With a TP53 Germline Mutation: A Case Report and Literature Review. <i>Journal of Pediatric Hematology/Oncology</i> , 2019, 41, 399-401.	0.3	4
105	The mechanistic basis for chromatin regulation by pioneer transcription factors. <i>Wiley Interdisciplinary Reviews: Systems Biology and Medicine</i> , 2019, 11, e1427.	6.6	72
106	Targeting Therapies for the p53 Protein in Cancer Treatments. <i>Annual Review of Cancer Biology</i> , 2019, 3, 21-34.	2.3	65
107	Inhibition of APE1-endonuclease activity affects cell metabolism in colon cancer cells via a p53-dependent pathway. <i>DNA Repair</i> , 2019, 82, 102675.	1.3	31
108	A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies. <i>Science</i> , 2019, 365, 599-604.	6.0	265

#	ARTICLE	IF	CITATIONS
109	Proteasome Activation to Combat Proteotoxicity. <i>Molecules</i> , 2019, 24, 2841.	1.7	29
110	The role of TP53 in acute myeloid leukemia: Challenges and opportunities. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 875-888.	1.5	79
111	Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches. <i>Radiation Oncology</i> , 2019, 14, 141.	1.2	285
112	TP53 DNA Binding Domain Mutations Predict Progression-Free Survival of Bevacizumab Therapy in Metastatic Colorectal Cancer. <i>Cancers</i> , 2019, 11, 1079.	1.7	6
113	CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan. <i>Nature Communications</i> , 2019, 10, 3637.	5.8	170
114	SLMP53-2 Restores Wild-Type-Like Function to Mutant p53 through Hsp70: Promising Activity in Hepatocellular Carcinoma. <i>Cancers</i> , 2019, 11, 1151.	1.7	21
115	Experimental Models for Preclinical Research in Hepatocellular Carcinoma. <i>Molecular and Translational Medicine</i> , 2019, , 333-358.	0.4	7
116	Which are the most promising targets for minimal residual disease-directed therapy in acute myeloid leukemia prior to allogeneic stem cell transplant?. <i>Haematologica</i> , 2019, 104, 1521-1531.	1.7	18
117	Precision medicine for TP53-mutated acute myeloid leukemia. <i>Expert Review of Precision Medicine and Drug Development</i> , 2019, 4, 263-274.	0.4	2
118	Global views of proteasome-mediated degradation by mass spectrometry. <i>Expert Review of Proteomics</i> , 2019, 16, 711-716.	1.3	6
119	Machine learning and data mining frameworks for predicting drug response in cancer: An overview and a novel in silico screening process based on association rule mining. , 2019, 203, 107395.		76
121	Eiger/TNF α -mediated Dilp8 and ROS production coordinate intra-organ growth in <i>Drosophila</i> . <i>PLoS Genetics</i> , 2019, 15, e1008133.	1.5	33
122	Functional Toll-Like Receptors (TLRs) Are Expressed by a Majority of Primary Human Acute Myeloid Leukemia Cells and Inducibility of the TLR Signaling Pathway Is Associated with a More Favorable Phenotype. <i>Cancers</i> , 2019, 11, 973.	1.7	29
123	p53 modifications: exquisite decorations of the powerful guardian. <i>Journal of Molecular Cell Biology</i> , 2019, 11, 564-577.	1.5	260
124	Deciphering the mechanism for induction of senescence-associated secretory phenotype (SASP) and its role in ageing and cancer development. <i>Journal of Biochemistry</i> , 2019, 166, 289-295.	0.9	32
125	Inhibition of p53 inhibitors: progress, challenges and perspectives. <i>Journal of Molecular Cell Biology</i> , 2019, 11, 586-599.	1.5	107
126	TGF β 1 α p53 cooperativity regulates a profibrotic genomic program in the kidney: molecular mechanisms and clinical implications. <i>FASEB Journal</i> , 2019, 33, 10596-10606.	0.2	17
127	Global views of proteasome-mediated degradation by mass spectrometry. <i>Expert Review of Proteomics</i> , 2019, , .	1.3	1

#	ARTICLE	IF	CITATIONS
128	p53 and Development: Shedding Light on an Evolutionary Enigma. <i>Developmental Cell</i> , 2019, 50, 128-129.	3.1	2
129	E3 Ubiquitin Ligases in Cancer and Their Pharmacological Targeting. , 2019, , .		3
130	Upregulation of nucleoprotein AHNAK is associated with poor outcome of pancreatic ductal adenocarcinoma prognosis via mediating epithelial-mesenchymal transition. <i>Journal of Cancer</i> , 2019, 10, 3860-3870.	1.2	26
131	Analysis of TP53 gene in uterine myomas: No mutations but P72R polymorphism is associated with myoma development. <i>Journal of Obstetrics and Gynaecology Research</i> , 2019, 45, 2088-2094.	0.6	1
132	Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas. <i>Cell Reports</i> , 2019, 28, 1370-1384.e5.	2.9	382
133	Transcriptome signature of cellular senescence. <i>Nucleic Acids Research</i> , 2019, 47, 7294-7305.	6.5	185
134	TP53 Mutations Promote Immunogenic Activity in Breast Cancer. <i>Journal of Oncology</i> , 2019, 2019, 1-19.	0.6	51
135	The R882H substitution in the human de novo DNA methyltransferase DNMT3A disrupts allosteric regulation by the tumor suppressor p53. <i>Journal of Biological Chemistry</i> , 2019, 294, 18207-18219.	1.6	9
136	Sox2+ cells in Sonic Hedgehog-subtype medulloblastoma resist p53-mediated cell-cycle arrest response and drive therapy-induced recurrence. <i>Neuro-Oncology Advances</i> , 2019, 1, vdz027.	0.4	5
137	p53 mitotic centrosome localization preserves centrosome integrity and works as sensor for the mitotic surveillance pathway. <i>Cell Death and Disease</i> , 2019, 10, 850.	2.7	26
138	Mutant p53 drives cancer chemotherapy resistance due to loss of function on activating transcription of PUMA. <i>Cell Cycle</i> , 2019, 18, 3442-3455.	1.3	48
139	Enhancing the Cell Permeability of Stapled Peptides with a Cyclic Cell-Penetrating Peptide. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 10098-10107.	2.9	61
140	Antitumor immunity augments the therapeutic effects of p53 activation on acute myeloid leukemia. <i>Nature Communications</i> , 2019, 10, 4869.	5.8	36
141	DMPK is a New Candidate Mediator of Tumor Suppressor p53-Dependent Cell Death. <i>Molecules</i> , 2019, 24, 3175.	1.7	7
142	Negative feedback and time delay regulate p53 oscillation in response to DNA damage. , 2019, , .		1
143	P53-R273H mutation enhances colorectal cancer stemness through regulating specific lncRNAs. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 379.	3.5	59
144	p53 nuclear accumulation as an early indicator of lethal prostate cancer. <i>British Journal of Cancer</i> , 2019, 121, 578-583.	2.9	10
145	Antiproliferative activity of vanadium compounds: effects on the major malignant melanoma molecular pathways. <i>Metallomics</i> , 2019, 11, 1687-1699.	1.0	41

#	ARTICLE	IF	CITATIONS
146	Neural Stem Cells of the Subventricular Zone as the Origin of Human Glioblastoma Stem Cells. Therapeutic Implications. <i>Frontiers in Oncology</i> , 2019, 9, 779.	1.3	78
147	Targeted Sequencing of Tubo-ovarian and Peritoneal High-grade Serous Carcinoma With Wild-type p53 Immunostaining Pattern. <i>In Vivo</i> , 2019, 33, 1485-1492.	0.6	9
148	IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 397.	3.5	111
149	DREAM and RB cooperate to induce gene repression and cell-cycle arrest in response to p53 activation. <i>Nucleic Acids Research</i> , 2019, 47, 9087-9103.	6.5	61
150	Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Nonâ€“Small Cell Lung Cancer. <i>JAMA Network Open</i> , 2019, 2, e1911895.	2.8	55
151	Î±-Ketoglutarate links p53 to cell fate during tumour suppression. <i>Nature</i> , 2019, 573, 595-599.	13.7	187
152	The Drosophila Model in Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2019, , .	0.8	4
153	Ubiquitin ligase TRIM71 suppresses ovarian tumorigenesis by degrading mutant p53. <i>Cell Death and Disease</i> , 2019, 10, 737.	2.7	31
154	The Role of the Cyclin Dependent Kinase Inhibitor p21cip1/waf1 in Targeting Cancer: Molecular Mechanisms and Novel Therapeutics. <i>Cancers</i> , 2019, 11, 1475.	1.7	116
155	Kinetic and thermodynamic effects of phosphorylation on p53 binding to MDM2. <i>Scientific Reports</i> , 2019, 9, 693.	1.6	25
156	High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma. <i>Blood</i> , 2019, 133, 1217-1221.	0.6	79
157	Wild-Type p53 Promotes Cancer Metabolic Switch by Inducing PLUMA-Dependent Suppression of Oxidative Phosphorylation. <i>Cancer Cell</i> , 2019, 35, 191-203.e8.	7.7	139
158	Isoprenylcysteine carboxy methyltransferase (ICMT) is associated with tumor aggressiveness and its expression is controlled by the p53 tumor suppressor. <i>Journal of Biological Chemistry</i> , 2019, 294, 5060-5073.	1.6	15
159	Targeted OMA1 therapies for cancer. <i>International Journal of Cancer</i> , 2019, 145, 2330-2341.	2.3	26
160	Control of p53-dependent transcription and enhancer activity by the p53 family member p63. <i>Journal of Biological Chemistry</i> , 2019, 294, 10720-10736.	1.6	27
161	Robust elimination of genome-damaged cells safeguards against brain somatic aneuploidy following Knl1 deletion. <i>Nature Communications</i> , 2019, 10, 2588.	5.8	35
162	Genetic basis of ruminant headgear and rapid antler regeneration. <i>Science</i> , 2019, 364, .	6.0	121
163	Dual Farnesyl and Geranylgeranyl Transferase Inhibitor Thwarts Mutant KRAS-Driven Patient-Derived Pancreatic Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 5984-5996.	3.2	46

#	ARTICLE	IF	CITATIONS
164	Analysis of the TP53 Deleterious Single Nucleotide Polymorphisms Impact on Estrogen Receptor Alpha-p53 Interaction: A Machine Learning Approach. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2962.	1.8	8
165	An integrated transcriptional switch at the \hat{I}^2 -selection checkpoint determines T cell survival, development and leukaemogenesis. <i>Biochemical Society Transactions</i> , 2019, 47, 1077-1089.	1.6	9
166	The Spatiotemporal Pattern and Intensity of p53 Activation Dictates Phenotypic Diversity in p53-Driven Developmental Syndromes. <i>Developmental Cell</i> , 2019, 50, 212-228.e6.	3.1	48
167	Targeted Genomic Sequencing Reveals Novel TP53 In-frame Deletion Mutations Leading to p53 Overexpression in High-grade Serous Tubo-ovarian Carcinoma. <i>Anticancer Research</i> , 2019, 39, 2883-2889.	0.5	21
168	p53-Dependent Anti-Proliferative and Pro-Apoptotic Effects of a Gold(I) N-Heterocyclic Carbene (NHC) Complex in Colorectal Cancer Cells. <i>Frontiers in Oncology</i> , 2019, 9, 438.	1.3	34
169	Modulated electro-hyperthermia induced p53 driven apoptosis and cell cycle arrest additively support doxorubicin chemotherapy of colorectal cancer in vitro. <i>Cancer Medicine</i> , 2019, 8, 4292-4303.	1.3	36
170	ZCCHC10 suppresses lung cancer progression and cisplatin resistance by attenuating MDM2-mediated p53 ubiquitination and degradation. <i>Cell Death and Disease</i> , 2019, 10, 414.	2.7	16
171	Trp53 null and R270H mutant alleles have comparable effects in regulating invasion, metastasis, and gene expression in mouse colon tumorigenesis. <i>Laboratory Investigation</i> , 2019, 99, 1454-1469.	1.7	18
172	Opposing effects of acute versus chronic inhibition of p53 on decitabine's efficacy in myeloid neoplasms. <i>Scientific Reports</i> , 2019, 9, 8171.	1.6	10
173	Determinants of nutrient limitation in cancer. <i>Critical Reviews in Biochemistry and Molecular Biology</i> , 2019, 54, 193-207.	2.3	36
174	The chemistry of senescence. <i>Nature Reviews Chemistry</i> , 2019, 3, 426-441.	13.8	88
175	Marine Carotenoid Fucoxanthin Possesses Anti-Metastasis Activity: Molecular Evidence. <i>Marine Drugs</i> , 2019, 17, 338.	2.2	34
176	p53 mutation regulates PKD genes and results in co-occurrence of PKD and tumorigenesis. <i>Cancer Biology and Medicine</i> , 2019, 16, 79.	1.4	9
177	A Gain-of-Function p53-Mutant Oncogene Promotes Cell Fate Plasticity and Myeloid Leukemia through the Pluripotency Factor FOXH1. <i>Cancer Discovery</i> , 2019, 9, 962-979.	7.7	58
178	A Trans-Ethnic Genome-Wide Association Study of Uterine Fibroids. <i>Frontiers in Genetics</i> , 2019, 10, 511.	1.1	32
179	Nucleoporin Nup155 is part of the p53 network in liver cancer. <i>Nature Communications</i> , 2019, 10, 2147.	5.8	29
180	Antiproliferative and toxicogenomic effects of resveratrol in bladder cancer cells with different TP53 status. <i>Environmental and Molecular Mutagenesis</i> , 2019, 60, 740-751.	0.9	25
181	Coordinated Conformational Processing of the Tumor Suppressor Protein p53 by the Hsp70 and Hsp90 Chaperone Machineries. <i>Molecular Cell</i> , 2019, 74, 816-830.e7.	4.5	61

#	ARTICLE	IF	CITATIONS
182	Prevalence of p53 dysregulations in feline oral squamous cell carcinoma and non-neoplastic oral mucosa. PLoS ONE, 2019, 14, e0215621.	1.1	18
183	Identification of Kinases Responsible for p53-Dependent Autophagy. IScience, 2019, 15, 109-118.	1.9	4
184	The many faces of p53: something for everyone. Journal of Molecular Cell Biology, 2019, 11, 524-530.	1.5	108
185	Porcine epidemic diarrhea virus infections induce apoptosis in Vero cells via a reactive oxygen species (ROS)/p53, but not p38 MAPK and SAPK/JNK signalling pathways. Veterinary Microbiology, 2019, 232, 1-12.	0.8	55
186	TP53 Status as a Determinant of Pro- vs Anti-Tumorigenic Effects of Estrogen Receptor-Beta in Breast Cancer. Journal of the National Cancer Institute, 2019, 111, 1202-1215.	3.0	39
187	p53 expression status is associated with cancer-specific survival in stage III and high-risk stage II colorectal cancer patients treated with oxaliplatin-based adjuvant chemotherapy. British Journal of Cancer, 2019, 120, 797-805.	2.9	32
188	Knockdown of the TP53-Induced Glycolysis and Apoptosis Regulator (TIGAR) Sensitizes Glioma Cells to Hypoxia, Irradiation and Temozolomide. International Journal of Molecular Sciences, 2019, 20, 1061.	1.8	11
189	Emerging Therapies for Acute Myelogenous Leukemia Patients Targeting Apoptosis and Mitochondrial Metabolism. Cancers, 2019, 11, 260.	1.7	28
190	Wild type p53 function in p53Y220C mutant harboring cells by treatment with Ashwagandha derived anticancer withanolides: bioinformatics and experimental evidence. Journal of Experimental and Clinical Cancer Research, 2019, 38, 103.	3.5	24
191	Inhibition of DYRK1A-EGFR axis by p53-MDM2 cascade mediates the induction of cellular senescence. Cell Death and Disease, 2019, 10, 282.	2.7	25
192	Mutant p53 regulates LPA signaling through lysophosphatidic acid phosphatase type 6. Scientific Reports, 2019, 9, 5195.	1.6	16
193	The long and the short of it: the MDM4 tail so far. Journal of Molecular Cell Biology, 2019, 11, 231-244.	1.5	52
194	Functional Diversity of p53 in Human and Wild Animals. Frontiers in Endocrinology, 2019, 10, 152.	1.5	20
195	Genome-wide screening identifies novel genes and biological processes implicated in cisplatin resistance. FASEB Journal, 2019, 33, 7143-7154.	0.2	18
196	Spindle Assembly Checkpoint Inhibition Can Resensitize p53-Null Stem Cells to Cancer Chemotherapy. Cancer Research, 2019, 79, 2392-2403.	0.4	14
197	p53 Promotes Cancer Cell Adaptation to Glutamine Deprivation by Upregulating Slc7a3 to Increase Arginine Uptake. Cell Reports, 2019, 26, 3051-3060.e4.	2.9	71
198	Modeling genotypes in their microenvironment to predict single- and multi-cellular behavior. GigaScience, 2019, 8, .	3.3	14
199	p53-targeted lincRNA-p21 acts as a tumor suppressor by inhibiting JAK2/STAT3 signaling pathways in head and neck squamous cell carcinoma. Molecular Cancer, 2019, 18, 38.	7.9	88

#	ARTICLE	IF	CITATIONS
200	ALOX12 is required for p53-mediated tumour suppression through a distinct ferroptosis pathway. <i>Nature Cell Biology</i> , 2019, 21, 579-591.	4.6	486
201	Mechanistic basis for impaired ferroptosis in cells expressing the African-centric S47 variant of p53. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 8390-8396.	3.3	72
202	Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer. <i>Lung Cancer</i> , 2019, 132, 65-71.	0.9	120
203	FASN activity is important for the initial stages of the induction of senescence. <i>Cell Death and Disease</i> , 2019, 10, 318.	2.7	54
204	Thermal Reduction of Graphene Oxide Mitigates Its In Vivo Genotoxicity Toward <i>Xenopus laevis</i> Tadpoles. <i>Nanomaterials</i> , 2019, 9, 584.	1.9	28
205	PCNA-Mediated Degradation of p21 Coordinates the DNA Damage Response and Cell Cycle Regulation in Individual Cells. <i>Cell Reports</i> , 2019, 27, 48-58.e7.	2.9	28
206	Natural killer cells limit the clearance of senescent lung adenocarcinoma cells. <i>Oncogenesis</i> , 2019, 8, 24.	2.1	14
207	Genetics of Familial and Sporadic Pancreatic Cancer. <i>Gastroenterology</i> , 2019, 156, 2041-2055.	0.6	52
208	Interactions of p53 with poly(ADP-ribose) and DNA induce distinct changes in protein structure as revealed by ATR-FTIR spectroscopy. <i>Nucleic Acids Research</i> , 2019, 47, 4843-4858.	6.5	20
209	LncRNA EPB41L4A-AS1 regulates glycolysis and glutaminolysis by mediating nucleolar translocation of HDAC2. <i>EBioMedicine</i> , 2019, 41, 200-213.	2.7	116
210	The prognostic impact of TP53 comutation in EGFR mutant lung cancer patients: a systematic review and meta-analysis. <i>Postgraduate Medicine</i> , 2019, 131, 199-206.	0.9	21
211	Genome Damage Sensing Leads to Tissue Homeostasis in <i>Drosophila</i> . <i>International Review of Cell and Molecular Biology</i> , 2019, 345, 173-224.	1.6	13
212	PRMT5 Modulates Splicing for Genome Integrity and Preserves Proteostasis of Hematopoietic Stem Cells. <i>Cell Reports</i> , 2019, 26, 2316-2328.e6.	2.9	75
213	NFAT5 is Regulated by p53/miR-27a Signal Axis and Promotes Mouse Ovarian Granulosa Cells Proliferation. <i>International Journal of Biological Sciences</i> , 2019, 15, 287-297.	2.6	15
214	TP53LNC-DB, the database of lncRNAs in the p53 signalling network. <i>Database: the Journal of Biological Databases and Curation</i> , 2019, 2019, .	1.4	7
215	Exploratory analyses of consensus molecular subtype-dependent associations of TP53 mutations with immunomodulation and prognosis in colorectal cancer. <i>ESMO Open</i> , 2019, 4, e000523.	2.0	11
216	ISG15 Deficiency Enhances HIV-1 Infection by Accumulating Misfolded p53. <i>MBio</i> , 2019, 10, .	1.8	19
217	Loss of p53 function at late stages of tumorigenesis confers ARF-dependent vulnerability to p53 reactivation therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 22288-22293.	3.3	14

#	ARTICLE	IF	CITATIONS
218	Transformed bone marrow cells generate neoplasms of distinct histogenesis. a murine model of cancer transplantation. <i>Stem Cell Research</i> , 2019, 41, 101637.	0.3	0
219	Identification of cancer sex-disparity in the functional integrity of p53 and its X chromosome network. <i>Nature Communications</i> , 2019, 10, 5385.	5.8	53
220	Transcriptomic characterization of culture-associated changes in murine and human precision-cut tissue slices. <i>Archives of Toxicology</i> , 2019, 93, 3549-3583.	1.9	26
221	Genome-wide CRISPR Screen to Identify Genes that Suppress Transformation in the Presence of Endogenous KrasG12D. <i>Scientific Reports</i> , 2019, 9, 17220.	1.6	6
222	Bcl-2-associated athanogene 5 (BAG5) regulates Parkin-dependent mitophagy and cell death. <i>Cell Death and Disease</i> , 2019, 10, 907.	2.7	32
223	A Small Compound KJ-28d Enhances the Sensitivity of Non-Small Cell Lung Cancer to Radio- and Chemotherapy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 6026.	1.8	7
224	PKM2: A Potential Regulator of Rheumatoid Arthritis via Glycolytic and Non-Glycolytic Pathways. <i>Frontiers in Immunology</i> , 2019, 10, 2919.	2.2	40
225	<p>Strategies For Targeting Chronic Myeloid Leukaemia Stem Cells</p>. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2019, Volume 9, 45-52.	1.2	6
226	p53-Mediated Tumor Suppression: DNA-Damage Response and Alternative Mechanisms. <i>Cancers</i> , 2019, 11, 1983.	1.7	53
227	The Emerging Landscape of p53 Isoforms in Physiology, Cancer and Degenerative Diseases. <i>International Journal of Molecular Sciences</i> , 2019, 20, 6257.	1.8	52
228	The Diverse Functions of Mutant 53, Its Family Members and Isoforms in Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 6188.	1.8	11
229	The Neglectable Impact of Delayed Graft Function on Long-term Graft Survival in Kidneys Donated After Circulatory Death Associates With Superior Organ Resilience. <i>Annals of Surgery</i> , 2019, 270, 877-883.	2.1	32
230	New spirobisanthralenes from an endolichenic fungus strain CGMCC 3.15192 and their anticancer effects through the P53â€P21 pathway. <i>RSC Advances</i> , 2019, 9, 39082-39089.	1.7	6
231	Cell death pathologies: targeting death pathways and the immune system for cancer therapy. <i>Genes and Immunity</i> , 2019, 20, 539-554.	2.2	39
232	p53 Represses the Mevalonate Pathway to Mediate Tumor Suppression. <i>Cell</i> , 2019, 176, 564-580.e19.	13.5	269
233	<i>p53</i> deletion rescues lethal microcephaly in a mouse model with neural stem cell abscission defects. <i>Human Molecular Genetics</i> , 2019, 28, 434-447.	1.4	34
234	Interferon-stimulated gene 15 enters posttranslational modifications of p53. <i>Journal of Cellular Physiology</i> , 2019, 234, 5507-5518.	2.0	4
235	miR-192-5p Silencing by Genetic Aberrations Is a Key Event in Hepatocellular Carcinomas with Cancer Stem Cell Features. <i>Cancer Research</i> , 2019, 79, 941-953.	0.4	65

#	ARTICLE	IF	CITATIONS
236	Mutant p53 in cancer therapy—the barrier or the path. <i>Journal of Molecular Cell Biology</i> , 2019, 11, 293-305.	1.5	165
237	PDCD4 Is an Androgen-Repressed Tumor Suppressor that Regulates Prostate Cancer Growth and Castration Resistance. <i>Molecular Cancer Research</i> , 2019, 17, 618-627.	1.5	23
238	Urolithin A induces prostate cancer cell death in p53-dependent and in p53-independent manner. <i>European Journal of Nutrition</i> , 2020, 59, 1607-1618.	1.8	36
239	Context is everything: aneuploidy in cancer. <i>Nature Reviews Genetics</i> , 2020, 21, 44-62.	7.7	407
240	GRWD1 directly interacts with p53 and negatively regulates p53 transcriptional activity. <i>Journal of Biochemistry</i> , 2020, 167, 15-24.	0.9	9
241	The Immune Microenvironment and Cancer Metastasis. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2020, 10, a037424.	2.9	57
242	Prion-like p53 Amyloids in Cancer. <i>Biochemistry</i> , 2020, 59, 146-155.	1.2	42
243	Short-term hypoxia promotes vascularization in co-culture system consisting of primary human osteoblasts and outgrowth endothelial cells. <i>Journal of Biomedical Materials Research - Part A</i> , 2020, 108, 7-18.	2.1	21
244	Role of Asparagine Endopeptidase in Mediating Wild-Type p53 Inactivation of Glioblastoma. <i>Journal of the National Cancer Institute</i> , 2020, 112, 343-355.	3.0	25
245	Inactivation of Wild-Type p53 by Asparagine Endopeptidase in Glioblastoma: An Opportunity to Target the “Undruggable”. <i>Journal of the National Cancer Institute</i> , 2020, 112, 327-329.	3.0	0
246	The RNA-binding protein RBM47 is a novel regulator of cell fate decisions by transcriptionally controlling the p53-p21-axis. <i>Cell Death and Differentiation</i> , 2020, 27, 1274-1285.	5.0	39
247	An update on the central nervous system manifestations of Li-Fraumeni syndrome. <i>Acta Neuropathologica</i> , 2020, 139, 669-687.	3.9	44
248	At a glance: A history of autophagy and cancer. <i>Seminars in Cancer Biology</i> , 2020, 66, 3-11.	4.3	70
249	Regulation of the MDM2-p53 pathway by the ubiquitin ligase HERC2. <i>Molecular Oncology</i> , 2020, 14, 69-86.	2.1	27
250	Qualitative control of undesired oscillations in a genetic negative feedback loop with uncertain measurements. <i>Automatica</i> , 2020, 112, 108642.	3.0	3
251	Targeting intrinsically disordered proteins involved in cancer. <i>Cellular and Molecular Life Sciences</i> , 2020, 77, 1695-1707.	2.4	74
252	The role of acetylation sites in the regulation of p53 activity. <i>Molecular Biology Reports</i> , 2020, 47, 381-391.	1.0	15
253	Strategies for the Development of Metallic-Nanoparticle-Based Label-Free Biosensors and Their Biomedical Applications. <i>ChemBioChem</i> , 2020, 21, 576-600.	1.3	34

#	ARTICLE	IF	CITATIONS
254	Cancer progression is mediated by proline catabolism in non-small cell lung cancer. <i>Oncogene</i> , 2020, 39, 2358-2376.	2.6	51
255	BRCA1/P53: Two strengths in cancer chemoprevention. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2020, 1873, 188339.	3.3	17
256	Genotoxins exaggerate the stressed state of aneuploid embryonic stem cells via activation of autophagy. <i>Science China Life Sciences</i> , 2020, 63, 1026-1036.	2.3	2
257	TP53 Gain-of-Function Mutations in Circulating Tumor DNA in Men With Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 148-154.	0.9	7
258	Extracellular Vesicle-Mediated Communication between the Glioblastoma and Its Microenvironment. <i>Cells</i> , 2020, 9, 96.	1.8	60
259	Synthetic lethality: a step forward for personalized medicine in cancer. <i>Drug Discovery Today</i> , 2020, 25, 305-320.	3.2	17
260	Competitive ubiquitination activates the tumor suppressor p53. <i>Cell Death and Differentiation</i> , 2020, 27, 1807-1818.	5.0	27
261	Inactivation of Mdm2 restores apoptosis proficiency of cooperativity mutant p53 in vivo. <i>Cell Cycle</i> , 2020, 19, 109-123.	1.3	8
262	Combination of a novel microtubule inhibitor MBRI-001 and gemcitabine synergistically induces cell apoptosis by increasing DNA damage in pancreatic cancer cell lines. <i>Investigational New Drugs</i> , 2020, 38, 1207-1217.	1.2	4
263	Tumor Biology and Metastasis. , 2020, , 36-60.		0
264	Mutant p53 on the Path to Metastasis. <i>Trends in Cancer</i> , 2020, 6, 62-73.	3.8	85
265	Natural Agents Targeting Mitochondria in Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6992.	1.8	44
266	When Endoplasmic Reticulum Proteostasis Meets the DNA Damage Response. <i>Trends in Cell Biology</i> , 2020, 30, 881-891.	3.6	55
267	Analysis of U8 snoRNA Variants in Zebrafish Reveals How Bi-allelic Variants Cause Leukoencephalopathy with Calcifications and Cysts. <i>American Journal of Human Genetics</i> , 2020, 106, 694-706.	2.6	17
268	Protein phosphatase 1 in tumorigenesis: is it worth a closer look?. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2020, 1874, 188433.	3.3	20
269	MYBL2 amplification in breast cancer: Molecular mechanisms and therapeutic potential. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2020, 1874, 188407.	3.3	35
270	The intergenerational toxic effects on offspring of medaka fish <i>Oryzias melastigma</i> from parental benzo[a]pyrene exposure via interference of the circadian rhythm. <i>Environmental Pollution</i> , 2020, 267, 115437.	3.7	17
271	Identification of Small Molecules that Modulate Mutant p53 Condensation. <i>IScience</i> , 2020, 23, 101517.	1.9	26

#	ARTICLE	IF	CITATIONS
272	Consequences of Zmat3 loss in c-MYC- and mutant KRAS-driven tumorigenesis. <i>Cell Death and Disease</i> , 2020, 11, 877.	2.7	7
273	Comparative Oncology: New Insights into an Ancient Disease. <i>IScience</i> , 2020, 23, 101373.	1.9	23
274	A p53/lncâ€p53 Negative Feedback Loop Regulates Tumor Growth and Chemoresistance. <i>Advanced Science</i> , 2020, 7, 2001364.	5.6	26
275	Tetrandrine enhances antitumor effects of the histone deacetylase inhibitor MS-275 in human cancer in a Bax- and p53-dependent manner. <i>European Journal of Pharmacology</i> , 2020, 888, 173575.	1.7	3
276	p53 immunostaining cannot be used to predict TP53 mutations in gastric cancer: results from a large Central European cohort. <i>Human Pathology</i> , 2020, 105, 53-66.	1.1	16
277	Recent advances of molecular mechanisms of regulating PD-L1 expression in melanoma. <i>International Immunopharmacology</i> , 2020, 88, 106971.	1.7	7
278	c-Myc inactivation of p53 through the pan-cancer lncRNA MILIP drives cancer pathogenesis. <i>Nature Communications</i> , 2020, 11, 4980.	5.8	70
279	Comprehensive Molecular Characterization of Squamous Cell Carcinomas. , 2020, , .		1
280	Proposing novel MDM2 inhibitors: Combined physicsâ€driven highâ€throughput virtual screening and in vitro studies. <i>Chemical Biology and Drug Design</i> , 2020, 96, 684-700.	1.5	4
281	Educational Updates in Hematology Book: 25th Congress of the European Hematology Association, Virtual Edition 2020. <i>HemaSphere</i> , 2020, 4, .	1.2	2
282	The pseudo-caspase FLIP(L) regulates cell fate following p53 activation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 17808-17819.	3.3	18
283	Translation control can shape TP53-dependent cell fate. <i>Molecular and Cellular Oncology</i> , 2020, 7, 1767483.	0.3	2
284	The mechanistic GEMMs of oncogenic histones. <i>Human Molecular Genetics</i> , 2020, 29, R226-R235.	1.4	1
285	Association of Germline Variants in Human DNA Damage Repair Genes and Response to Adjuvant Chemotherapy in Resected Pancreatic Ductal Adenocarcinoma. <i>Journal of the American College of Surgeons</i> , 2020, 231, 527-535.e14.	0.2	11
286	A Molecular Stratification of Chilean Gastric Cancer Patients with Potential Clinical Applicability. <i>Cancers</i> , 2020, 12, 1863.	1.7	13
287	Aging of the cells: Insight into cellular senescence and detection Methods. <i>European Journal of Cell Biology</i> , 2020, 99, 151108.	1.6	100
288	Unprovoked Stabilization and Nuclear Accumulation of the Naked Mole-Rat p53 Protein. <i>Scientific Reports</i> , 2020, 10, 6966.	1.6	18
289	Heterogeneity of TP53 Mutations and P53 Protein Residual Function in Cancer: Does It Matter?. <i>Frontiers in Oncology</i> , 2020, 10, 593383.	1.3	50

#	ARTICLE	IF	CITATIONS
290	<p>Characteristics and Management of TP53-Mutated Diffuse Large B-Cell Lymphoma Patients</p>. Cancer Management and Research, 2020, Volume 12, 11515-11522.	0.9	8
291	Loss of the spectraplaklin gene Short stop induces a DNA damage response in Drosophila epithelia. Scientific Reports, 2020, 10, 20165.	1.6	4
292	Apoptosis targeted therapies in acute myeloid leukemia: an update. Expert Review of Hematology, 2020, 13, 1373-1386.	1.0	12
293	Genetic Mutations and Variants in the Susceptibility of Familial Non-Medullary Thyroid Cancer. Genes, 2020, 11, 1364.	1.0	10
294	Host cell p53 associates with the feline calicivirus major viral capsid protein VP1, the protease-polymerase NS6/7, and the double-stranded RNA playing a role in virus replication. Virology, 2020, 550, 78-88.	1.1	1
295	Heparanase and the hallmarks of cancer. Journal of Translational Medicine, 2020, 18, 453.	1.8	78
296	miR-10a as a therapeutic target and predictive biomarker for MDM2 inhibition in acute myeloid leukemia. Leukemia, 2021, 35, 1933-1948.	3.3	22
297	The Regulation of Ferroptosis by Tumor Suppressor p53 and its Pathway. International Journal of Molecular Sciences, 2020, 21, 8387.	1.8	122
298	Triangular Relationship between p53, Autophagy, and Chemotherapy Resistance. International Journal of Molecular Sciences, 2020, 21, 8991.	1.8	40
299	The 40bp Indel Polymorphism rs150550023 in the MDM2 Promoter is Associated with Intriguing Shifts in Gene Expression in the p53-MDM2 Regulatory Hub. Cancers, 2020, 12, 3363.	1.7	3
300	Detection of somatic TP53 mutation in surgically resected small-cell lung cancer by targeted exome sequencing: association with longer relapse-free survival. Heliyon, 2020, 6, e04439.	1.4	7
301	Yin Yang 1 is critical for mid-hindbrain neuroepithelium development and involved in cerebellar agenesis. Molecular Brain, 2020, 13, 104.	1.3	13
302	Emergence of a High-Plasticity Cell State during Lung Cancer Evolution. Cancer Cell, 2020, 38, 229-246.e13.	7.7	210
303	MDMX phosphorylation-dependent p53 downregulation contributes to an immunosuppressive tumor microenvironment. Journal of Molecular Cell Biology, 2020, 12, 713-722.	1.5	7
304	Hotspot mutant p53-R273H inhibits KLF6 expression to promote cell migration and tumor metastasis. Cell Death and Disease, 2020, 11, 595.	2.7	15
305	Defining relative mutational difficulty to understand cancer formation. Cell Discovery, 2020, 6, 48.	3.1	4
306	Antibody-Drug Conjugates: The New Frontier of Chemotherapy. International Journal of Molecular Sciences, 2020, 21, 5510.	1.8	83
307	SPARC-p53: The double agents of cancer. Advances in Cancer Research, 2020, 148, 171-199.	1.9	18

#	ARTICLE	IF	CITATIONS
308	Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. <i>Nature Medicine</i> , 2020, 26, 1549-1556.	15.2	372
309	Non-coding RNAs, metabolic stress and adaptive mechanisms in cancer. <i>Cancer Letters</i> , 2020, 491, 60-69.	3.2	10
310	Single-cell transcriptomic analysis in a mouse model deciphers cell transition states in the multistep development of esophageal cancer. <i>Nature Communications</i> , 2020, 11, 3715.	5.8	79
311	Toxicogenetic and antiproliferative effects of chrysin in urinary bladder cancer cells. <i>Mutagenesis</i> , 2020, 35, 361-371.	1.0	15
312	BRAFV600E drives dedifferentiation in small intestinal and colonic organoids and cooperates with mutant p53 and Apc loss in transformation. <i>Oncogene</i> , 2020, 39, 6053-6070.	2.6	19
313	Circulating MicroRNAs from Serum Exosomes May Serve as a Putative Biomarker in the Diagnosis and Treatment of Patients with Focal Cortical Dysplasia. <i>Cells</i> , 2020, 9, 1867.	1.8	10
314	The P72R Polymorphism in R248Q/W p53 Mutants Modifies the Mutant Effect on Epithelial to Mesenchymal Transition Phenotype and Cell Invasion via CXCL1 Expression. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8025.	1.8	4
315	<p>¹³³p53/FLp53 Predicts Poor Clinical Outcome in Esophageal Squamous Cell Carcinoma</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 7405-7417.	0.9	6
316	Immunometabolic function of the transcription cofactor VGLL3 provides an evolutionary rationale for sexual dimorphism in autoimmunity. <i>FEBS Letters</i> , 2020, 594, 3371-3383.	1.3	9
317	Roles of NRF3 in the Hallmarks of Cancer: Proteasomal Inactivation of Tumor Suppressors. <i>Cancers</i> , 2020, 12, 2681.	1.7	23
318	RBM10, a New Regulator of p53. <i>Cells</i> , 2020, 9, 2107.	1.8	18
319	Oncogenic TRIM37 Links Chemoresistance and Metastatic Fate in Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2020, 80, 4791-4804.	0.4	15
320	Enhancing Chemotherapy of p53-Mutated Cancer through Ubiquitination-Dependent Proteasomal Degradation of Mutant p53 Proteins by Engineered ZnFe ₄ Nanoparticles. <i>Advanced Functional Materials</i> , 2020, 30, 2001994.	7.8	18
321	Circular RNA CDR1as disrupts the p53/MDM2 complex to inhibit Gliomagenesis. <i>Molecular Cancer</i> , 2020, 19, 138.	7.9	122
322	Radioresistance in Glioblastoma and the Development of Radiosensitizers. <i>Cancers</i> , 2020, 12, 2511.	1.7	77
323	The hallmarks of cancer are also the hallmarks of wound healing. <i>Science Signaling</i> , 2020, 13, .	1.6	102
324	Male-biased aganglionic megacolon in the TashT mouse model of Hirschsprung disease involves upregulation of p53 protein activity and Ddx3y gene expression. <i>PLoS Genetics</i> , 2020, 16, e1009008.	1.5	6
325	UFMylation maintains tumour suppressor p53 stability by antagonizing its ubiquitination. <i>Nature Cell Biology</i> , 2020, 22, 1056-1063.	4.6	91

#	ARTICLE	IF	CITATIONS
326	Functional effects of chimeric antigen receptor co-receptor signaling domains in human regulatory T cells. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	89
327	Acute Myeloid Leukemia and Myelodysplastic Syndromes with <i>TP53</i> Aberrations – A Distinct Stem Cell Disorder. <i>Clinical Cancer Research</i> , 2020, 26, 5304-5309.	3.2	11
328	The Oncogenic Roles of PTTG1 and PTTG2 Genes and Pseudogene PTTG3P in Head and Neck Squamous Cell Carcinomas. <i>Diagnostics</i> , 2020, 10, 606.	1.3	9
329	Comprehensive assessment of TP53 loss of function using multiple combinatorial mutagenesis libraries. <i>Scientific Reports</i> , 2020, 10, 20368.	1.6	12
330	The PARP Inhibitor Olaparib Modulates the Transcriptional Regulatory Networks of Long Non-Coding RNAs during Vasculogenic Mimicry. <i>Cells</i> , 2020, 9, 2690.	1.8	5
331	Hemispherical Pediatric High-Grade Glioma: Molecular Basis and Therapeutic Opportunities. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9654.	1.8	16
332	Regulation of hepatocyte cell cycle re-entry by RNA polymerase II-associated Gdown1. <i>Cell Cycle</i> , 2020, 19, 3222-3230.	1.3	4
333	Reticulon 3-mediated Chk2/p53 activation suppresses hepatocellular carcinogenesis and is blocked by hepatitis B virus. <i>Gut</i> , 2021, 70, 2159-2171.	6.1	27
334	Non-disruptive mutation in TP53 DNA-binding domain is a beneficial factor of esophageal squamous cell carcinoma. <i>Annals of Translational Medicine</i> , 2020, 8, 316-316.	0.7	12
335	Analysis of <i>TP53</i> aflatoxin signature mutation in hepatocellular carcinomas from Guatemala: A cross-sectional study (2016–2017). <i>Health Science Reports</i> , 2020, 3, e155.	0.6	4
336	Use of p53 immunohistochemistry in conjunction with routine histology improves risk stratification of patients with Barrett's oesophagus during routine clinical care. <i>Histopathology</i> , 2020, 77, 481-491.	1.6	9
337	p53: 800 million years of evolution and 40 years of discovery. <i>Nature Reviews Cancer</i> , 2020, 20, 471-480.	12.8	421
338	Ovarian BDNF promotes survival, migration, and attachment of tumor precursors originated from p53 mutant fallopian tube epithelial cells. <i>Oncogenesis</i> , 2020, 9, 55.	2.1	8
339	LncRNA H19 promotes triple-negative breast cancer cells invasion and metastasis through the p53/TNFAIP8 pathway. <i>Cancer Cell International</i> , 2020, 20, 200.	1.8	40
340	Mdm4 controls ureteric bud branching via regulation of p53 activity. <i>Mechanisms of Development</i> , 2020, 163, 103616.	1.7	2
341	GLIS2 promotes colorectal cancer through repressing enhancer activation. <i>Oncogenesis</i> , 2020, 9, 57.	2.1	19
342	Molecular profiling of Chinese R-CHOP treated DLBCL patients: Identifying a high-risk subgroup. <i>International Journal of Cancer</i> , 2020, 147, 2611-2620.	2.3	12
343	Transcriptional down-regulation of metabolic genes by Gdown1 ablation induces quiescent cell re-entry into the cell cycle. <i>Genes and Development</i> , 2020, 34, 767-784.	2.7	5

#	ARTICLE	IF	CITATIONS
344	Chromatin remodelers in oligodendroglia. <i>Glia</i> , 2020, 68, 1604-1618.	2.5	15
345	Design, synthesis and evaluation of novel levoglucosenone derivatives as promising anticancer agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 127247.	1.0	16
346	Immunosensors containing solution blow spun fibers of poly(lactic acid) to detect p53 biomarker. <i>Materials Science and Engineering C</i> , 2020, 115, 111120.	3.8	7
347	BH3 mimetics selectively eliminate chemotherapy-induced senescent cells and improve response in TP53 wild-type breast cancer. <i>Cell Death and Differentiation</i> , 2020, 27, 3097-3116.	5.0	70
348	Tumour predisposition and cancer syndromes as models to study gene-environment interactions. <i>Nature Reviews Cancer</i> , 2020, 20, 533-549.	12.8	93
349	Regulating tumor suppressor genes: post-translational modifications. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 90.	7.1	193
350	Downregulated brain and muscle aryl hydrocarbon receptor nuclear translocator-like protein-1 inhibits osteogenesis of BMSCs through p53 in type 2 diabetes mellitus. <i>Biology Open</i> , 2020, 9, .	0.6	9
351	Age-related epigenetic drift deregulates <i>SIRT6</i> expression and affects its downstream genes in human peripheral blood mononuclear cells. <i>Epigenetics</i> , 2020, 15, 1336-1347.	1.3	5
352	Transformation of Hematopoietic Stem and Progenitor Cells by Leukemia Extracellular Vesicles: A Step Toward Leukemogenesis. <i>Stem Cell Reviews and Reports</i> , 2020, 16, 1081-1091.	1.7	7
353	HOXA5 inhibits the proliferation and neoplasia of cervical cancer cells via downregulating the activity of the Wnt/ β -catenin pathway and transactivating TP53. <i>Cell Death and Disease</i> , 2020, 11, 420.	2.7	26
354	Sample-based modeling reveals bidirectional interplay between cell cycle progression and extrinsic apoptosis. <i>PLoS Computational Biology</i> , 2020, 16, e1007812.	1.5	6
355	Association of the Epithelial-Mesenchymal Transition (EMT) with Cisplatin Resistance. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4002.	1.8	160
356	Lineage Reversion Drives WNT Independence in Intestinal Cancer. <i>Cancer Discovery</i> , 2020, 10, 1590-1609.	7.7	52
357	TP53 dysfunction in chronic lymphocytic leukemia: clinical relevance in the era of B-cell receptors and BCL-2 inhibitors. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 869-880.	1.9	10
358	NEK10 tyrosine phosphorylates p53 and controls its transcriptional activity. <i>Oncogene</i> , 2020, 39, 5252-5266.	2.6	12
359	Expression of the Long Noncoding RNA DINO in Human Papillomavirus-Positive Cervical Cancer Cells Reactivates the Dormant TP53 Tumor Suppressor through ATM/CHK2 Signaling. <i>MBio</i> , 2020, 11, .	1.8	19
360	Wnt/ β -catenin activation cooperates with loss of p53 to cause adrenocortical carcinoma in mice. <i>Oncogene</i> , 2020, 39, 5282-5291.	2.6	30
361	The prognostic significance of immune microenvironment in breast ductal carcinoma in situ. <i>British Journal of Cancer</i> , 2020, 122, 1496-1506.	2.9	26

#	ARTICLE	IF	CITATIONS
362	Molecular-Genetic Features of Pancreatic Neuroendocrine Tumors. Russian Journal of Genetics, 2020, 56, 142-158.	0.2	0
363	Role of p53 in the Regulation of Cellular Senescence. Biomolecules, 2020, 10, 420.	1.8	267
364	Dual regulation of p53 by the ribosome maturation factor SBDS. Cell Death and Disease, 2020, 11, 197.	2.7	22
365	The role of noncoding RNAs in epithelial cancer. Cell Death Discovery, 2020, 6, 13.	2.0	34
366	Emerging Mechanisms and Disease Relevance of Ferroptosis. Trends in Cell Biology, 2020, 30, 478-490.	3.6	624
367	Context is everything: extrinsic signalling and gain-of-function p53 mutants. Cell Death Discovery, 2020, 6, 16.	2.0	38
368	Targeting apoptosis in cancer therapy. Nature Reviews Clinical Oncology, 2020, 17, 395-417.	12.5	1,192
369	Network hub-node prioritization of gene regulation with intra-network association. BMC Bioinformatics, 2020, 21, 101.	1.2	12
370	Functional Classification of TP53 Mutations in Acute Myeloid Leukemia. Cancers, 2020, 12, 637.	1.7	42
371	Folding and structural polymorphism of p53's C-terminal domain: One peptide with many conformations. Archives of Biochemistry and Biophysics, 2020, 684, 108342.	1.4	24
372	MK2 Inhibition Induces p53-Dependent Senescence in Glioblastoma Cells. Cancers, 2020, 12, 654.	1.7	5
373	Heterozygous p53-R280T Mutation Enhances the Oncogenicity of NPC Cells Through Activating PI3K-Akt Signaling Pathway. Frontiers in Oncology, 2020, 10, 104.	1.3	14
374	Cytotoxic Activity of Organotin(IV) Derivatives with Triazolopyrimidine Containing Exocyclic Oxygen Atoms. Molecules, 2020, 25, 859.	1.7	20
375	WDR63 inhibits Arp2/3-dependent actin polymerization and mediates the function of p53 in suppressing metastasis. EMBO Reports, 2020, 21, e49269.	2.0	16
376	The Global Phosphorylation Landscape of SARS-CoV-2 Infection. Cell, 2020, 182, 685-712.e19.	13.5	825
377	Testicular cancer: Determinants of cisplatin sensitivity and novel therapeutic opportunities. Cancer Treatment Reviews, 2020, 88, 102054.	3.4	76
378	Shikonin Inhibits Cancer Through P21 Upregulation and Apoptosis Induction. Frontiers in Pharmacology, 2020, 11, 861.	1.6	36
379	The role of MDM2-p53 axis dysfunction in the hepatocellular carcinoma transformation. Cell Death Discovery, 2020, 6, 53.	2.0	49

#	ARTICLE	IF	CITATIONS
380	A systematic approach to decipher crosstalk in the p53 signaling pathway using single cell dynamics. <i>PLoS Computational Biology</i> , 2020, 16, e1007901.	1.5	12
381	Genetic mutation profile of Chinese HER2-positive breast cancers and genetic predictors of responses to Neoadjuvant anti-HER2 therapy. <i>Breast Cancer Research and Treatment</i> , 2020, 183, 321-332.	1.1	6
382	The Multifaceted Role of Heme in Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 1540.	1.3	80
383	Driver mutations in acute myeloid leukemia. <i>Current Opinion in Hematology</i> , 2020, 27, 49-57.	1.2	44
384	Hypomethylation-Linked Activation of PLCE1 Impedes Autophagy and Promotes Tumorigenesis through MDM2-Mediated Ubiquitination and Destabilization of p53. <i>Cancer Research</i> , 2020, 80, 2175-2189.	0.4	21
385	p53's Extended Reach: The Mutant p53 Secretome. <i>Biomolecules</i> , 2020, 10, 307.	1.8	35
386	p53-Related Transcription Targets of TAp73 in Cancer Cells "Bona Fide or Distorted Reality?". <i>International Journal of Molecular Sciences</i> , 2020, 21, 1346.	1.8	10
387	Inhibition of urinary bladder cancer cell proliferation by silibinin. <i>Environmental and Molecular Mutagenesis</i> , 2020, 61, 445-455.	0.9	21
388	LINE-1 retrotransposon encoded ORF1p expression and promoter methylation in oral squamous cell carcinoma: a pilot study. <i>Cancer Genetics</i> , 2020, 244, 21-29.	0.2	8
389	TP53 Mutations and Outcomes in Breast Cancer: Reading beyond the Headlines. <i>Trends in Cancer</i> , 2020, 6, 98-110.	3.8	81
390	Tumor protein 53 mutations in acute myeloid leukemia: conventional induction chemotherapy or novel therapeutics. <i>Current Opinion in Hematology</i> , 2020, 27, 66-75.	1.2	6
391	Fluorinated derivatives of 2-phenyl-3-hydroxy-4(1H)-quinolinone as tubulin polymerization inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2020, 192, 112176.	2.6	12
392	p53 Mutant p53 ^{N236S} Regulates Cancer-Associated Fibroblasts Properties Through Stat3 Pathway. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 1355-1363.	1.0	17
393	Involvement of p53 Acetylation in Growth Suppression of Cutaneous T-Cell Lymphomas Induced by HDAC Inhibition. <i>Journal of Investigative Dermatology</i> , 2020, 140, 2009-2022.e4.	0.3	15
394	20(S)-Protopanaxatriol promotes the binding of P53 and DNA to regulate the antitumor network via multiomic analysis. <i>Acta Pharmaceutica Sinica B</i> , 2020, 10, 1020-1035.	5.7	18
395	Ubiquitin-specific proteases as targets for anticancer drug therapies. , 2020, , 73-120.		2
396	PTEN as a Guardian of the Genome: Pathways and Targets. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2020, 10, a036194.	2.9	14
397	CRISPR/CAS9-based DNA damage response screens reveal gene-drug interactions. <i>DNA Repair</i> , 2020, 87, 102803.	1.3	23

#	ARTICLE	IF	CITATIONS
398	Prognosis, Biology, and Targeting of TP53 Dysregulation in Multiple Myeloma. <i>Cells</i> , 2020, 9, 287.	1.8	37
399	Bacterial Genotoxin-Induced DNA Damage and Modulation of the Host Immune Microenvironment. <i>Toxins</i> , 2020, 12, 63.	1.5	39
400	TRIM25 and its emerging RNA-binding roles in antiviral defense. <i>Wiley Interdisciplinary Reviews RNA</i> , 2020, 11, e1588.	3.2	37
401	The GTPase KRAS suppresses the p53 tumor suppressor by activating the NRF2-regulated antioxidant defense system in cancer cells. <i>Journal of Biological Chemistry</i> , 2020, 295, 3055-3063.	1.6	17
402	Emerging next-generation sequencing-based discoveries for targeted osteosarcoma therapy. <i>Cancer Letters</i> , 2020, 474, 158-167.	3.2	54
403	Chloropicrin-induced toxicity in the respiratory system. <i>Toxicology Letters</i> , 2020, 323, 10-18.	0.4	16
404	A Mouse Homolog of a Human TP53 Germline Mutation Reveals a Lipolytic Activity of p53. <i>Cell Reports</i> , 2020, 30, 783-792.e5.	2.9	12
405	WIP1 dephosphorylation of p27Kip1 Serine 140 destabilizes p27Kip1 and reverses anti-proliferative effects of ATM phosphorylation. <i>Cell Cycle</i> , 2020, 19, 479-491.	1.3	11
406	FBXW7 Confers Radiation Survival by Targeting p53 for Degradation. <i>Cell Reports</i> , 2020, 30, 497-509.e4.	2.9	53
407	Cancer type-dependent correlations between TP53 mutations and antitumor immunity. <i>DNA Repair</i> , 2020, 88, 102785.	1.3	100
408	The Progressive Mutagenic Effects of Acidic Bile Refluxate in Hypopharyngeal Squamous Cell Carcinogenesis: New Insights. <i>Cancers</i> , 2020, 12, 1064.	1.7	12
409	Structural basis for DNA damage-induced phosphoregulation of MDM2 RING domain. <i>Nature Communications</i> , 2020, 11, 2094.	5.8	20
410	Comparison of gene disruption induced by cytosine base editing-mediated iSTOP with CRISPR/Cas9-mediated frameshift. <i>Cell Proliferation</i> , 2020, 53, e12820.	2.4	6
411	Sphingolipids and the link between alcohol and cancer. <i>Chemico-Biological Interactions</i> , 2020, 322, 109058.	1.7	16
412	Genome-wide Screens Implicate Loss of Cullin Ring Ligase 3 in Persistent Proliferation and Genome Instability in TP53-Deficient Cells. <i>Cell Reports</i> , 2020, 31, 107465.	2.9	24
413	The p53 Saga: Early Steps in the Development of Tumor Immunotherapy. <i>Journal of Immunology</i> , 2020, 204, 2321-2328.	0.4	8
414	Targeting Apoptosis in Acute Myeloid Leukemia: Current Status and Future Directions of BCL-2 Inhibition with Venetoclax and Beyond. <i>Targeted Oncology</i> , 2020, 15, 147-162.	1.7	27
415	PI3K Inhibitors Curtail MYC-Dependent Mutant p53 Gain-of-Function in Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 2956-2971.	3.2	33

#	ARTICLE	IF	CITATIONS
416	Stromal-MDM2 Promotes Lung Cancer Cell Invasion through Tumor-Host Feedback Signaling. <i>Molecular Cancer Research</i> , 2020, 18, 926-937.	1.5	8
417	Sex differences in cancer mechanisms. <i>Biology of Sex Differences</i> , 2020, 11, 17.	1.8	169
418	Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes. <i>Blood Advances</i> , 2020, 4, 482-495.	2.5	86
419	p53, cancer and the immune response. <i>Journal of Cell Science</i> , 2020, 133, .	1.2	190
420	The Role of Somatic Mutations in Acute Myeloid Leukemia Pathogenesis. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2021, 11, a034975.	2.9	8
421	Drugging "undruggable" genes for cancer treatment: Are we making progress?. <i>International Journal of Cancer</i> , 2021, 148, 8-17.	2.3	63
422	Mutant TP53 interacts with BCAR1 to contribute to cancer cell invasion. <i>British Journal of Cancer</i> , 2021, 124, 299-312.	2.9	10
423	Potency and Selectivity Optimization of Tryptophan-Derived Oxazoloisoindolinones: Novel p53 Activators in Human Colorectal Cancer. <i>ChemMedChem</i> , 2021, 16, 250-258.	1.6	6
424	Gene dysregulation analysis builds a mechanistic signature for prognosis and therapeutic benefit in colorectal cancer. <i>Journal of Molecular Cell Biology</i> , 2021, 12, 881-893.	1.5	3
425	Context is key: Understanding the regulation, functional control, and activities of the p53 tumour suppressor. <i>Cell Biochemistry and Function</i> , 2021, 39, 235-247.	1.4	16
426	Functional benefit and molecular mechanism of vitamin C against perfluorooctanesulfonate-associated leukemia. <i>Chemosphere</i> , 2021, 263, 128242.	4.2	15
427	Wnt-induced, TRP53-mediated Cell Cycle Arrest of Precursors Underlies Interstitial Cell of Cajal Depletion During Aging. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021, 11, 117-145.	2.3	9
428	p53 Is Not Required for High CIN to Induce Tumor Suppression. <i>Molecular Cancer Research</i> , 2021, 19, 112-123.	1.5	11
429	The current landscape of molecular profiling in the treatment of epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 160, 333-345.	0.6	40
430	Aggressive PDACs Show Hypomethylation of Repetitive Elements and the Execution of an Intrinsic IFN Program Linked to a Ductal Cell of Origin. <i>Cancer Discovery</i> , 2021, 11, 638-659.	7.7	65
431	A mechanistic review: potential chronic disease-preventive properties of sorghum. <i>Journal of the Science of Food and Agriculture</i> , 2021, 101, 2641-2649.	1.7	8
432	Three Primary Tumors Including EGFR-mutated Non-Small Cell Lung Cancer as First Presentation in Patient With Li-Fraumeni Syndrome. <i>Clinical Lung Cancer</i> , 2021, 22, e116-e121.	1.1	0
433	Dysregulation of lysophospholipid signaling by p53 in malignant cells and the tumor microenvironment. <i>Cellular Signalling</i> , 2021, 78, 109850.	1.7	6

#	ARTICLE	IF	CITATIONS
434	In silico analysis of the association of hsa-miR-16 expression and cell survival in MDA-MB-231 breast cancer cells subjected to photodynamic therapy. <i>Photodiagnosis and Photodynamic Therapy</i> , 2021, 33, 102106.	1.3	2
435	Emerging roles for HMGA2 in colorectal cancer. <i>Translational Oncology</i> , 2021, 14, 100894.	1.7	22
436	Identification and functional characterization of new missense SNPs in the coding region of the TP53 gene. <i>Cell Death and Differentiation</i> , 2021, 28, 1477-1492.	5.0	26
437	The utility of TP53 and PIK3CA mutations as prognostic biomarkers in salivary adenoid cystic carcinoma. <i>Oral Oncology</i> , 2021, 113, 105095.	0.8	14
438	Encorafenib enhances TRAIL-induced apoptosis of colorectal cancer cells dependent on p53/PUMA signaling. <i>Cytotechnology</i> , 2021, 73, 63-70.	0.7	3
439	The Wnt/ β -Catenin Pathway is Activated as a Novel Nucleolar Stress Response. <i>Journal of Molecular Biology</i> , 2021, 433, 166719.	2.0	15
440	The characteristics and roles of β -TrCP1/2 in carcinogenesis. <i>FEBS Journal</i> , 2021, 288, 3351-3374.	2.2	32
441	Identification of a druggable protein-protein interaction site between mutant p53 and its stabilizing chaperone DNAJA1. <i>Journal of Biological Chemistry</i> , 2021, 296, 100098.	1.6	20
442	Senescence Reprogramming by TIMP1 Deficiency Promotes Prostate Cancer Metastasis. <i>Cancer Cell</i> , 2021, 39, 68-82.e9.	7.7	66
443	mTOR inhibition acts as an unexpected checkpoint in p53-mediated tumor suppression. <i>Genes and Development</i> , 2021, 35, 59-64.	2.7	31
444	Mutant p53 as a Regulator and Target of Autophagy. <i>Frontiers in Oncology</i> , 2020, 10, 607149.	1.3	32
445	Lisofylline mitigates cardiac inflammation in a mouse model of obesity through improving insulin secretion and activating cardiac AMPK signaling pathway. <i>Cytokine</i> , 2021, 138, 155398.	1.4	2
446	Quercetin induces p53-independent cancer cell death through lysosome activation by the transcription factor EB and Reactive Oxygen Species-dependent ferroptosis. <i>British Journal of Pharmacology</i> , 2021, 178, 1133-1148.	2.7	113
447	Immune landscape and a promising immune prognostic model associated with TP53 in early-stage lung adenocarcinoma. <i>Cancer Medicine</i> , 2021, 10, 806-823.	1.3	17
448	Mutant p53 Gain-of-Function: Role in Cancer Development, Progression, and Therapeutic Approaches. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 607670.	1.8	64
449	LncRNA-mediated posttranslational modifications and reprogramming of energy metabolism in cancer. <i>Cancer Communications</i> , 2021, 41, 109-120.	3.7	271
450	Precise and error-prone CRISPR-directed gene editing activity in human CD34+ cells varies widely among patient samples. <i>Gene Therapy</i> , 2021, 28, 105-113.	2.3	12
451	The role of p53/p21/p16 in DNA damage signaling and DNA repair. , 2021, , 257-274.		2

#	ARTICLE	IF	CITATIONS
452	Gain of GAS5 reveals worse prognosis in kidney renal clear cell carcinoma and liver hepatocellular carcinoma from the Cancer Genome Atlas dataset. <i>Translational Cancer Research</i> , 2021, 10, 223-232.	0.4	0
453	Synthesis of RNA-based gene regulatory devices for redirecting cellular signaling events mediated by p53. <i>Theranostics</i> , 2021, 11, 4688-4698.	4.6	2
454	Deficiency of telomere-associated repressor activator protein 1 precipitates cardiac aging in mice via p53/PPAR α signaling. <i>Theranostics</i> , 2021, 11, 4710-4727.	4.6	18
455	Tumor Suppressor Genes and Cell Fate Control. , 2021, , 29-40.		0
456	Anticancer Activities of Plant Secondary Metabolites: Rice Callus Suspension Culture as a New Paradigm. <i>Rice Science</i> , 2021, 28, 13-30.	1.7	22
457	Novel modulators of p53-signaling encoded by unknown genes of emerging viruses. <i>PLoS Pathogens</i> , 2021, 17, e1009033.	2.1	12
459	Cellular senescence in the aging retina and developments of senotherapies for age-related macular degeneration. <i>Journal of Neuroinflammation</i> , 2021, 18, 32.	3.1	62
460	Distinct mechanisms control genome recognition by p53 at its target genes linked to different cell fates. <i>Nature Communications</i> , 2021, 12, 484.	5.8	22
461	p53, A Victim of the Prion Fashion. <i>Cancers</i> , 2021, 13, 269.	1.7	8
462	DNA folds threaten genetic stability and can be leveraged for chemotherapy. <i>RSC Chemical Biology</i> , 2021, 2, 47-76.	2.0	39
463	Heterogeneity Analysis of Esophageal Squamous Cell Carcinoma in Cell Lines, Tumor Tissues and Patient-Derived Xenografts. <i>Journal of Cancer</i> , 2021, 12, 3930-3944.	1.2	13
464	Resveratrol effects in bladder cancer: A mini review. <i>Genetics and Molecular Biology</i> , 2021, 44, e20200371.	0.6	9
465	PathVisio Analysis: An Application Targeting the miRNA Network Associated with the p53 Signaling Pathway in Osteosarcoma. <i>Biocell</i> , 2021, 45, 17-26.	0.4	1
466	Possible relationship between mitochondrial changes and oxidative stress under low dose-rate irradiation. <i>Redox Report</i> , 2021, 26, 160-169.	1.4	15
467	p53-Independent Induction of p21 Fails to Control Regeneration and Hepatocarcinogenesis in a Murine Liver Injury Model. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021, 11, 1387-1404.	2.3	3
468	Transcriptomic and metabolomic profiling reveal the p53-dependent benzeneacetic acid attenuation of silica-induced epithelial-mesenchymal transition in human bronchial epithelial cells. <i>Cell and Bioscience</i> , 2021, 11, 30.	2.1	8
470	The transcription factor PBX3 promotes tumor cell growth through transcriptional suppression of the tumor suppressor p53. <i>Acta Pharmacologica Sinica</i> , 2021, 42, 1888-1899.	2.8	10
471	Network Analysis Identifies Drug Targets and Small Molecules to Modulate Apoptosis Resistant Cancers. <i>Cancers</i> , 2021, 13, 851.	1.7	6

#	ARTICLE	IF	CITATIONS
472	Integrative Genomic and Transcriptomic Analyses of Tumor Suppressor Genes and Their Role on Tumor Microenvironment and Immunity in Lung Squamous Cell Carcinoma. <i>Frontiers in Immunology</i> , 2021, 12, 598671.	2.2	11
473	Comparative Analysis of Stk11/Lkb1 versus Pten Deficiency in Lung Adenocarcinoma Induced by CRISPR/Cas9. <i>Cancers</i> , 2021, 13, 974.	1.7	14
474	Biomolecular Condensates and Cancer. <i>Cancer Cell</i> , 2021, 39, 174-192.	7.7	157
475	Gain-of-â€œendocyticâ€™ function in mutant p53 cancer cells. <i>International Journal of Biochemistry and Cell Biology</i> , 2021, 131, 105905.	1.2	3
476	Germline and Somatic Genetic Variants in the p53 Pathway Interact to Affect Cancer Risk, Progression, and Drug Response. <i>Cancer Research</i> , 2021, 81, 1667-1680.	0.4	32
477	Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications. <i>Acta Pharmacologica Sinica</i> , 2021, 42, 1725-1741.	2.8	53
478	Weakly Acidic Bile Is a Risk Factor for Hypopharyngeal Carcinogenesis Evidenced by DNA Damage, Antiapoptotic Function, and Premalignant Dysplastic Lesions In Vivo. <i>Cancers</i> , 2021, 13, 852.	1.7	17
479	p53 is a central regulator driving neurodegeneration caused by C9orf72 poly(PR). <i>Cell</i> , 2021, 184, 689-708.e20.	13.5	104
480	Regulation of p53 by E3s. <i>Cancers</i> , 2021, 13, 745.	1.7	17
481	Therapeutic Options for Patients with TP53 Deficient Chronic Lymphocytic Leukemia: Narrative Review. <i>Cancer Management and Research</i> , 2021, Volume 13, 1459-1476.	0.9	3
482	Transketolase regulates sensitivity to APR-246 in p53-null cells independently of oxidative stress modulation. <i>Scientific Reports</i> , 2021, 11, 4480.	1.6	5
483	Expression and Gene Regulation Network of Metabolic Enzyme Phosphoglycerate Mutase Enzyme 1 in Breast Cancer Based on Data Mining. <i>BioMed Research International</i> , 2021, 2021, 1-39.	0.9	1
484	Precision medicine for heart failure based on molecular mechanisms: The 2019 ISHR Research Achievement Award Lecture. <i>Journal of Molecular and Cellular Cardiology</i> , 2021, 152, 29-39.	0.9	3
485	Genome-wide association study of resistance to Mycobacterium tuberculosis infection identifies a locus at 10q26.2 in three distinct populations. <i>PLoS Genetics</i> , 2021, 17, e1009392.	1.5	17
487	TP53 modulates radiotherapy fraction size sensitivity in normal and malignant cells. <i>Scientific Reports</i> , 2021, 11, 7119.	1.6	11
488	Cooperation between oncogenic Ras and wild-type p53 stimulates STAT non-cell autonomously to promote tumor radioresistance. <i>Communications Biology</i> , 2021, 4, 374.	2.0	11
489	Recent advances in prognostication and treatment of polycythemia vera. <i>Faculty Reviews</i> , 2021, 10, 29.	1.7	2
490	Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis. <i>Blood Cancer Journal</i> , 2021, 11, 52.	2.8	5

#	ARTICLE	IF	CITATIONS
491	Disposable Stochastic Sensor Based on Deposition of a Nanolayer of Silver on Silk for Molecular Recognition of Specific Biomarkers. <i>Journal of the Electrochemical Society</i> , 2021, 168, 037515.	1.3	7
492	On the role of p53 in the cellular response to aneuploidy. <i>Cell Reports</i> , 2021, 34, 108892.	2.9	24
493	New physiological insights into the phenomena of deer antler: A unique model for skeletal tissue regeneration. <i>Journal of Orthopaedic Translation</i> , 2021, 27, 57-66.	1.9	16
494	The guardian's choice: how p53 enables context-specific decision-making in individual cells. <i>FEBS Journal</i> , 2022, 289, 40-52.	2.2	15
495	The complex role of SIRT7 in p53 stabilization: nucleophosmin joins the debate. <i>Molecular and Cellular Oncology</i> , 2021, 8, 1896349.	0.3	3
496	Mechanisms of Cellular Senescence: Cell Cycle Arrest and Senescence Associated Secretory Phenotype. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 645593.	1.8	608
497	Cellular models of development of ovarian high-grade serous carcinoma: A review of cell of origin and mechanisms of carcinogenesis. <i>Cell Proliferation</i> , 2021, 54, e13029.	2.4	22
498	An unexpected role for p53 in regulating cancer cell-intrinsic PD-1 by acetylation. <i>Science Advances</i> , 2021, 7, .	4.7	32
499	Ionizing Radiation Combined with PARP1 Inhibitor Reduces Radioresistance in Prostate Cancer with RB1/TP53 Loss. <i>Cancer Investigation</i> , 2021, 39, 423-434.	0.6	5
500	Increased Pathway Complexity Is a Prognostic Biomarker in Metastatic Castration-Resistant Prostate Cancer. <i>Cancers</i> , 2021, 13, 1588.	1.7	1
501	The complexity of p53-mediated metabolic regulation in tumor suppression. <i>Seminars in Cancer Biology</i> , 2022, 85, 4-32.	4.3	104
502	<sc>CircKDM4C</sc> upregulates <sc>P53</sc> by sponging hsa-miR-7b-5p to induce ferroptosis in acute myeloid leukemia. <i>Environmental Toxicology</i> , 2021, 36, 1288-1302.	2.1	37
503	Aberrant phase separation and cancer. <i>FEBS Journal</i> , 2022, 289, 17-39.	2.2	42
504	A novel histone deacetylase inhibitor LT-548-133-1 induces apoptosis by inhibiting HDAC and interfering with microtubule assembly in MCF-7 cells. <i>Investigational New Drugs</i> , 2021, 39, 1222-1231.	1.2	4
505	Compartments and Connections Within the Germinal Center. <i>Frontiers in Immunology</i> , 2021, 12, 659151.	2.2	8
507	Nlx2.5 Functions as a Conditional Tumor Suppressor Gene in Colorectal Cancer Cells via Acting as a Transcriptional Coactivator in p53-Mediated p21 Expression. <i>Frontiers in Oncology</i> , 2021, 11, 648045.	1.3	4
508	Harnessing Colloidal Self-Assembled Patterns (cSAPs) to Regulate Bacterial and Human Stem Cell Response at Biointerfaces <i>In Vitro</i> and <i>In Vivo</i> . <i>ACS Applied Materials & Interfaces</i> , 2021, 13, 20982-20994.	4.0	7
509	Long non-coding RNA Meg3 deficiency impairs glucose homeostasis and insulin signaling by inducing cellular senescence of hepatic endothelium in obesity. <i>Redox Biology</i> , 2021, 40, 101863.	3.9	27

#	ARTICLE	IF	CITATIONS
510	Prognostic Value of the TP53 Mutation Location in Metastatic Breast Cancer as Detected by Next-Generation Sequencing. <i>Cancer Management and Research</i> , 2021, Volume 13, 3303-3316.	0.9	5
511	Positive and Negative Regulation of Ferroptosis and Its Role in Maintaining Metabolic and Redox Homeostasis. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-13.	1.9	36
512	Cancer clocks in tumorigenesis: the p53 pathway and beyond. <i>Endocrine-Related Cancer</i> , 2021, 28, R95-R110.	1.6	7
513	Structural insight into the molecular mechanism of p53-mediated mitochondrial apoptosis. <i>Nature Communications</i> , 2021, 12, 2280.	5.8	33
514	p53 mediates target gene association with nuclear speckles for amplified RNA expression. <i>Molecular Cell</i> , 2021, 81, 1666-1681.e6.	4.5	41
516	The actin nucleation factors JMY and WHAMM enable a rapid Arp2/3 complex-mediated intrinsic pathway of apoptosis. <i>PLoS Genetics</i> , 2021, 17, e1009512.	1.5	13
517	Targeting p53 for Melanoma Treatment: Counteracting Tumour Proliferation, Dissemination and Therapeutic Resistance. <i>Cancers</i> , 2021, 13, 1648.	1.7	11
518	The foundational framework of tumors: Gametogenesis, p53, and cancer. <i>Seminars in Cancer Biology</i> , 2022, 81, 193-205.	4.3	5
519	The foggy world(s) of p63 isoform regulation in normal cells and cancer. <i>Journal of Pathology</i> , 2021, 254, 454-473.	2.1	15
520	Feasibility of Developing Radiotracers for MDM2: Synthesis and Preliminary Evaluation of an 18F-Labeled Analogue of the MDM2 Inhibitor SP-141. <i>Pharmaceuticals</i> , 2021, 14, 358.	1.7	2
521	Oncogenic <i>KRAS</i> Recruits an Expansive Transcriptional Network through Mutant p53 to Drive Pancreatic Cancer Metastasis. <i>Cancer Discovery</i> , 2021, 11, 2094-2111.	7.7	66
522	Centrosome Dynamics and Its Role in Inflammatory Response and Metastatic Process. <i>Biomolecules</i> , 2021, 11, 629.	1.8	5
523	Glioblastomas with primitive neuronal component harbor a distinct methylation and copy-number profile with inactivation of TP53, PTEN, and RB1. <i>Acta Neuropathologica</i> , 2021, 142, 179-189.	3.9	24
524	Progress and Prospects of Regulatory Functions Mediated by Nitric Oxide on Immunity and Immunotherapy. <i>Advanced Therapeutics</i> , 2021, 4, 2100032.	1.6	10
526	CUL4B Promotes Temozolomide Resistance in Gliomas by Epigenetically Repressing CDKN1A Transcription. <i>Frontiers in Oncology</i> , 2021, 11, 638802.	1.3	3
527	The Cross-Link between Ferroptosis and Kidney Diseases. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-12.	1.9	25
528	The Mechanism of Asparagine Endopeptidase in the Progression of Malignant Tumors: A Review. <i>Cells</i> , 2021, 10, 1153.	1.8	25
529	Bibenzyl analogue DS-1 inhibits MDM2-mediated p53 degradation and sensitizes apoptosis in lung cancer cells. <i>Phytomedicine</i> , 2021, 85, 153534.	2.3	8

#	ARTICLE	IF	CITATIONS
531	Mutant p53 Mediates Sensitivity to Cancer Treatment Agents in Oesophageal Adenocarcinoma Associated with MicroRNA and SLC7A11 Expression. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5547.	1.8	9
532	Coordinate regulation of the senescent state by selective autophagy. <i>Developmental Cell</i> , 2021, 56, 1512-1525.e7.	3.1	29
533	Phosphorylation of HIC1 (Hypermethylated in Cancer 1) Ser694 by ATM is essential for DNA repair. <i>Biochemical and Biophysical Research Communications</i> , 2021, 553, 51-57.	1.0	3
535	Endogenous p53 expression in human and mouse is not regulated by its 3'UTR. <i>ELife</i> , 2021, 10, .	2.8	15
536	Advances in targeting "undruggable" transcription factors with small molecules. <i>Nature Reviews Drug Discovery</i> , 2021, 20, 669-688.	21.5	152
537	Vanadium and Melanoma: A Systematic Review. <i>Metals</i> , 2021, 11, 828.	1.0	39
538	Rely on Each Other: DNA Binding Cooperativity Shapes p53 Functions in Tumor Suppression and Cancer Therapy. <i>Cancers</i> , 2021, 13, 2422.	1.7	6
539	The Role of the Meiotic Component in Reproduction of B-RAF-Mutated Melanoma: A Review and "Brainstorming" Session. , 0, , .		2
540	TP53 Mutational Status-Based Genomic Signature for Prognosis and Predicting Therapeutic Response in Pancreatic Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 665265.	1.8	6
541	Mechanisms of TP53 Pathway Inactivation in Embryonic and Somatic Cells"Relevance for Understanding (Germ Cell) Tumorigenesis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5377.	1.8	10
543	Robust expression of LINE-1 retrotransposon encoded proteins in oral squamous cell carcinoma. <i>BMC Cancer</i> , 2021, 21, 628.	1.1	2
544	Anti-proliferative and apoptotic effect of gemini curcumin in p53-wild type and p53-mutant colorectal cancer cell lines. <i>International Journal of Pharmaceutics</i> , 2021, 601, 120592.	2.6	14
545	Pharmacological inhibition of PI5P4K β 2 disrupts cell energy metabolism and selectively kills p53-null tumor cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	17
546	Long Noncoding RNAs at the Crossroads of Cell Cycle and Genome Integrity. <i>Trends in Genetics</i> , 2021, 37, 528-546.	2.9	23
547	p65BTK Is a Novel Biomarker and Therapeutic Target in Solid Tumors. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 690365.	1.8	7
548	Redefining cancer of unknown primary: Is precision medicine really shifting the paradigm?. <i>Cancer Treatment Reviews</i> , 2021, 97, 102204.	3.4	24
549	Podocalyxin in Normal Tissue and Epithelial Cancer. <i>Cancers</i> , 2021, 13, 2863.	1.7	18
550	A Novel Ruthenium-Fluvastatin Complex Downregulates SNCG Expression to Modulate Breast Carcinoma Cell Proliferation and Apoptosis via Activating the PI3K/Akt/mTOR/VEGF/MMP9 Pathway. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-34.	1.9	4

#	ARTICLE	IF	CITATIONS
551	Role of Dietary Antioxidants in p53-Mediated Cancer Chemoprevention and Tumor Suppression. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-18.	1.9	26
552	p53/p73 Protein Network in Colorectal Cancer and Other Human Malignancies. <i>Cancers</i> , 2021, 13, 2885.	1.7	8
553	Stem-Like Cell Populations, p53-Pathway Activation and Mechanisms of Recurrence in Sonic Hedgehog Medulloblastoma. <i>NeuroMolecular Medicine</i> , 2022, 24, 13-17.	1.8	5
554	Hyperoxia Inhibits Proliferation of Retinal Endothelial Cells in a Myc-Dependent Manner. <i>Life</i> , 2021, 11, 614.	1.1	4
555	Integrative analysis of multi-omics data highlighted TP53 as a potential diagnostic and prognostic biomarker of survival in breast invasive carcinoma patients. <i>Computational Biology and Chemistry</i> , 2021, 92, 107457.	1.1	1
556	Poly adenosine diphosphate-ribosylation, a promising target for colorectal cancer treatment. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 574-588.	0.8	2
557	RNA sequencing of long-term label-retaining colon cancer stem cells identifies novel regulators of quiescence. <i>IScience</i> , 2021, 24, 102618.	1.9	6
559	Influence of Different Age Cutoff Points on the Prediction of Prognosis of Cancer Patients Receiving ICIs and Potential Mechanistic Exploration. <i>Frontiers in Oncology</i> , 2021, 11, 670927.	1.3	9
560	Tumor suppressor p53 regulates intestinal type 2 immunity. <i>Nature Communications</i> , 2021, 12, 3371.	5.8	19
561	Epigenetic Regulation of Cancer Immune Cells. <i>Seminars in Cancer Biology</i> , 2021, , .	4.3	9
562	The role of regulated necrosis in endocrine diseases. <i>Nature Reviews Endocrinology</i> , 2021, 17, 497-510.	4.3	35
563	iPLA2 ² -mediated lipid detoxification controls p53-driven ferroptosis independent of GPX4. <i>Nature Communications</i> , 2021, 12, 3644.	5.8	153
564	Puma, noxa, p53, and p63 differentially mediate stress pathway induced apoptosis. <i>Cell Death and Disease</i> , 2021, 12, 659.	2.7	34
565	Identification of a Two-MicroRNA Signature in Plasma as a Novel Biomarker for Very Early Diagnosis of Breast Cancer. <i>Cancers</i> , 2021, 13, 2848.	1.7	14
566	SLC45A4 promotes glycolysis and prevents AMPK/ULK1-induced autophagy in TP53 mutant pancreatic ductal adenocarcinoma. <i>Journal of Gene Medicine</i> , 2021, 23, e3364.	1.4	4
567	Protein mimetic amyloid inhibitor potently abrogates cancer-associated mutant p53 aggregation and restores tumor suppressor function. <i>Nature Communications</i> , 2021, 12, 3962.	5.8	53
568	Identification of Autophagy-Related Genes as Targets for Senescence Induction Using a Customizable CRISPR-Based Suicide Switch Screen. <i>Molecular Cancer Research</i> , 2021, 19, 1613-1621.	1.5	6
569	Combined effects of low-dose gambogic acid and Na ¹³¹ I in drug-resistant non-small cell lung cancer cells. <i>Oncology Letters</i> , 2021, 22, 588.	0.8	2

#	ARTICLE	IF	CITATIONS
570	Direct evidence of cellular transformation by prion-like p53 amyloid infection. <i>Journal of Cell Science</i> , 2021, 134, .	1.2	15
571	T-17, a spirostanol saponin, inhibits p53-independent proliferation and p53-dependent migration of gastric cancer cells. <i>Steroids</i> , 2021, 170, 108828.	0.8	4
572	Mitochondrial apoptotic priming is a key determinant of cell fate upon p53 restoration. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	20
573	Shifting the paradigms for tumor suppression: lessons from the p53 field. <i>Oncogene</i> , 2021, 40, 4281-4290.	2.6	15
574	An E3 ligase guide to the galaxy of small-molecule-induced protein degradation. <i>Cell Chemical Biology</i> , 2021, 28, 1000-1013.	2.5	55
575	The molecular chaperone TRAP1 in cancer: From the basics of biology to pharmacological targeting. <i>Seminars in Cancer Biology</i> , 2021, 76, 45-53.	4.3	18
576	MYC-targeted WDR4 promotes proliferation, metastasis, and sorafenib resistance by inducing CCNB1 translation in hepatocellular carcinoma. <i>Cell Death and Disease</i> , 2021, 12, 691.	2.7	112
577	Structural and Drug Targeting Insights on Mutant p53. <i>Cancers</i> , 2021, 13, 3344.	1.7	38
578	PARP-Targeted Auger Therapy in p53 Mutant Colon Cancer Xenograft Mouse Models. <i>Molecular Pharmaceutics</i> , 2021, 18, 3418-3428.	2.3	16
579	Homeostatic apoptosis prevents competition-induced atrophy in follicular B cells. <i>Cell Reports</i> , 2021, 36, 109430.	2.9	3
580	D-Propranolol Impairs EGFR Trafficking and Destabilizes Mutant p53 Counteracting AKT Signaling and Tumor Malignancy. <i>Cancers</i> , 2021, 13, 3622.	1.7	5
581	Cellular Basis of Organotin(IV) Derivatives as Anticancer Metallodrugs: A Review. <i>Frontiers in Chemistry</i> , 2021, 9, 657599.	1.8	42
584	The Biological Function of TUSC7/miR-1224-3p Axis in Triple-Negative Breast Cancer. <i>Cancer Management and Research</i> , 2021, Volume 13, 5763-5774.	0.9	6
585	The p53 transcriptional response across tumor types reveals core and senescence-specific signatures modulated by long noncoding RNAs. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	15
586	Nuclear iASPP determines cell fate by selectively inhibiting either p53 or NF- κ B. <i>Cell Death Discovery</i> , 2021, 7, 195.	2.0	4
587	The Chk2-PKM2 axis promotes metabolic control of vasculogenic mimicry formation in p53-mutated triple-negative breast cancer. <i>Oncogene</i> , 2021, 40, 5262-5274.	2.6	11
588	Pharmacologic Activation of p53 Triggers Viral Mimicry Response Thereby Abolishing Tumor Immune Evasion and Promoting Antitumor Immunity. <i>Cancer Discovery</i> , 2021, 11, 3090-3105.	7.7	79
589	Role of Copper on Mitochondrial Function and Metabolism. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 711227.	1.6	189

#	ARTICLE	IF	CITATIONS
590	The β^{40} p53 isoform inhibits p53-dependent mRNA transcription and enables regulation by signal-specific transcription factors during p53 activation. <i>PLoS Biology</i> , 2021, 19, e3001364.	2.6	14
591	Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1876, 188556.	3.3	181
592	The effect of the TP53 and RB1 mutations on the survival of hepatocellular carcinoma patients with different racial backgrounds. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 1786-1796.	0.6	5
593	Aging: What We Can Learn From Elephants. <i>Frontiers in Aging</i> , 2021, 2, .	1.2	5
594	Development of Tailor-Made Dendrimer Ternary Complexes for Drug/Gene Co-Delivery in Cancer. <i>Pharmaceutics</i> , 2021, 13, 1256.	2.0	5
595	Immunohistochemical staining patterns of p53 predict the mutational status of TP53 in oral epithelial dysplasia. <i>Modern Pathology</i> , 2022, 35, 177-185.	2.9	13
596	p53 transcriptionally regulates SQLE to repress cholesterol synthesis and tumor growth. <i>EMBO Reports</i> , 2021, 22, e52537.	2.0	35
597	Ascorbate Inhibits Proliferation and Promotes Myeloid Differentiation in TP53-Mutant Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 709543.	1.3	11
598	Acquisition of aneuploidy drives mutant p53-associated gain-of-function phenotypes. <i>Nature Communications</i> , 2021, 12, 5184.	5.8	30
599	TP53 Mutation Related and Directly Regulated lncRNA Prognosis Markers in Hepatocellular Carcinoma. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 4427-4437.	1.0	5
600	Hemorrhagic areas as a histological prognosticator in oral cancer: A novel proposition. <i>Medical Hypotheses</i> , 2021, 154, 110642.	0.8	2
601	p53 is functionally inhibited in clear cell renal cell carcinoma (ccRCC): a mechanistic and correlative investigation into genetic and molecular characteristics. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3565-3576.	1.2	5
603	Targeting the p53 Pathway in CLL: State of the Art and Future Perspectives. <i>Cancers</i> , 2021, 13, 4681.	1.7	9
604	p53 mRNA Metabolism Links with the DNA Damage Response. <i>Genes</i> , 2021, 12, 1446.	1.0	13
605	Protein music of enhanced musicality by music style guided exploration of diverse amino acid properties. <i>Heliyon</i> , 2021, 7, e07933.	1.4	3
607	Targeting the Interplay between HDACs and DNA Damage Repair for Myeloma Therapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10406.	1.8	7
609	Progress and challenges in understanding the regulation and function of p53 dynamics. <i>Biochemical Society Transactions</i> , 2021, 49, 2123-2131.	1.6	4
610	Viral targeting of glioblastoma stem cells with patient-specific genetic and post-translational p53 deregulations. <i>Cell Reports</i> , 2021, 36, 109673.	2.9	6

#	ARTICLE	IF	CITATIONS
611	Potent pro-apoptotic combination therapy is highly effective in a broad range of cancers. <i>Cell Death and Differentiation</i> , 2021, , .	5.0	10
612	The ubiquitin-proteasome system in normal hearing and deafness. <i>Hearing Research</i> , 2022, 426, 108366.	0.9	2
613	Identification and validation of pivotal genes related to age-related meniscus degeneration based on gene expression profiling analysis and in vivo and in vitro models detection. <i>BMC Medical Genomics</i> , 2021, 14, 237.	0.7	1
614	Personalized Medicine for TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10105.	1.8	15
616	Targeting mutant p53 for cancer therapy: direct and indirect strategies. <i>Journal of Hematology and Oncology</i> , 2021, 14, 157.	6.9	190
617	Response to: The Role of Dual Inhibition of EGFR and Vascular EGF(R) in the Treatment of NSCLC With EGFR Mutation. <i>Journal of Thoracic Oncology</i> , 2021, 16, e72-e76.	0.5	0
618	A general approach to protein folding using thermostable exoshells. <i>Nature Communications</i> , 2021, 12, 5720.	5.8	7
619	p53-Dependent Repression: DREAM or Reality?. <i>Cancers</i> , 2021, 13, 4850.	1.7	12
620	Anticancer Effects and Mechanisms of OSW-1 Isolated From <i>Ornithogalum saundersiae</i> : A Review. <i>Frontiers in Oncology</i> , 2021, 11, 747718.	1.3	6
621	p53 induces a survival transcriptional response after nucleolar stress. <i>Molecular Biology of the Cell</i> , 2021, 32, ar3.	0.9	12
622	Global transcriptome profiling reveals antagonizing response of head kidney of juvenile common carp exposed to glyphosate. <i>Chemosphere</i> , 2021, 280, 130823.	4.2	4
623	Identification of CDCA2 as a Diagnostic and Prognostic Marker for Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 755814.	1.3	5
624	Reactive oxygen species: Role in carcinogenesis, cancer cell signaling and tumor progression. <i>Life Sciences</i> , 2021, 284, 119942.	2.0	69
625	Polo-like kinase 1 (PLK1) signaling in cancer and beyond. <i>Biochemical Pharmacology</i> , 2021, 193, 114747.	2.0	71
626	Deciphering the PTM codes of the tumor suppressor p53. <i>Journal of Molecular Cell Biology</i> , 2022, 13, 774-785.	1.5	19
627	BRD4-mediated repression of p53 is a target for combination therapy in AML. <i>Nature Communications</i> , 2021, 12, 241.	5.8	43
628	An Integrated Approach to Identify New Anti-Filarial Leads to Treat River Blindness, a Neglected Tropical Disease. <i>Pathogens</i> , 2021, 10, 71.	1.2	16
629	MHC Phosphopeptides: Promising Targets for Immunotherapy of Cancer and Other Chronic Diseases. <i>Molecular and Cellular Proteomics</i> , 2021, 20, 100112.	2.5	11

#	ARTICLE	IF	CITATIONS
630	Semisynthetic α -designer TM p53 sheds light on a phosphorylation α -acetylation relay. <i>Chemical Science</i> , 2021, 12, 8563-8570.	3.7	7
631	The <i>MDM2</i> inducible promoter folds into four-tetrad antiparallel G-quadruplexes targetable to fight malignant liposarcoma. <i>Nucleic Acids Research</i> , 2021, 49, 847-863.	6.5	23
632	Chromatin Accessibility Regulates Gene Expression and Correlates With Tumor-Infiltrating Immune Cells in Gastric Adenocarcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 609940.	1.3	12
633	The complex architecture of p53 binding sites. <i>Nucleic Acids Research</i> , 2021, 49, 1364-1382.	6.5	15
634	Advances in drug development for targeted therapies for glioblastoma. <i>Medicinal Research Reviews</i> , 2020, 40, 1950-1972.	5.0	7
635	P53 and Apoptosis in the <i>Drosophila</i> Model. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1167, 105-112.	0.8	11
636	Genomic Applications in Thyroid Cancer. , 2019, , 325-334.		1
637	Genetic biomarkers of drug resistance: A compass of prognosis and targeted therapy in acute myeloid leukemia. <i>Drug Resistance Updates</i> , 2020, 52, 100703.	6.5	25
638	Coding and noncoding somatic mutations in candidate genes in basal cell carcinoma. <i>Scientific Reports</i> , 2020, 10, 8005.	1.6	17
639	iASPP mediates p53 selectivity through a modular mechanism fine-tuning DNA recognition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 17470-17479.	3.3	20
640	Dual inhibition of DNA-PK and DNA polymerase theta overcomes radiation resistance induced by p53 deficiency. <i>NAR Cancer</i> , 2020, 2, zcaa038.	1.6	18
641	The Many Uses of p53 Immunohistochemistry in Gynecological Pathology: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual Meeting. <i>International Journal of Gynecological Pathology</i> , 2021, 40, 32-40.	0.9	37
652	New addiction to the NRF2-related factor NRF3 in cancer cells: Ubiquitin-independent proteolysis through the 20S proteasome. <i>Cancer Science</i> , 2020, 111, 6-14.	1.7	28
653	PLK1 Induces Chromosomal Instability and Overrides Cell-Cycle Checkpoints to Drive Tumorigenesis. <i>Cancer Research</i> , 2021, 81, 1293-1307.	0.4	39
654	Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers. <i>Journal of Clinical Investigation</i> , 2019, 129, 1109-1114.	3.9	193
655	Mechanisms and functions of cellular senescence. <i>Journal of Clinical Investigation</i> , 2018, 128, 1238-1246.	3.9	696
656	The essentials of developmental apoptosis. <i>F1000Research</i> , 2020, 9, 148.	0.8	84
657	The Tumor Suppressor, p53, Negatively Regulates Non-Canonical NF- κ B Signaling through miRNA-Induced Silencing of NF- κ B-Inducing Kinase. <i>Molecules and Cells</i> , 2020, 43, 23-33.	1.0	7

#	ARTICLE	IF	CITATIONS
658	PIDDosome-induced p53-dependent ploidy restriction facilitates hepatocarcinogenesis. <i>EMBO Reports</i> , 2020, 21, e50893.	2.0	29
659	Central role of the p53 pathway in the noncoding-RNA response to oxidative stress. <i>Aging</i> , 2017, 9, 2559-2586.	1.4	54
660	Silencing of lncRNA XIST inhibits non-small cell lung cancer growth and promotes chemosensitivity to cisplatin. <i>Aging</i> , 2020, 12, 4711-4726.	1.4	53
661	Exploring the molecular aspects associated with testicular germ cell tumors: a review. <i>Oncotarget</i> , 2018, 9, 1365-1379.	0.8	21
662	MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma. <i>Oncotarget</i> , 2018, 9, 20323-20338.	0.8	28
663	Biological significance and prognostic/predictive impact of complex karyotype in chronic lymphocytic leukemia. <i>Oncotarget</i> , 2018, 9, 34398-34412.	0.8	11
664	Inhibition of ATM kinase upregulates levels of cell death induced by cannabidiol and β -irradiation in human glioblastoma cells. <i>Oncotarget</i> , 2019, 10, 825-846.	0.8	21
665	MicroRNA-based regulation of Aurora A kinase in breast cancer. <i>Oncotarget</i> , 2020, 11, 4306-4324.	0.8	11
666	The molecular basis for p53 inhibition of autophagy in porcine fibroblast cells. <i>Translational Cancer Research</i> , 2019, 8, 876-886.	0.4	2
667	Pathophysiological Functions of the lncRNA TUG1. <i>Current Pharmaceutical Design</i> , 2020, 26, 688-700.	0.9	55
668	Targeting p53-MDM2 Interaction Using Small Molecule Inhibitors and the Challenges Needed to be Addressed. <i>Current Drug Targets</i> , 2019, 20, 1091-1111.	1.0	18
669	Biomarkers predicting oncological outcomes of high-risk non-muscle-invasive bladder cancer. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2020, 72, 265-278.	3.9	9
670	Effects of Thermal Stress and Ocean Acidification on the Expression of the Retrotransposon Steamer in the Softshell <i>Mya arenaria</i> . <i>Journal of Shellfish Research</i> , 2019, 38, 535.	0.3	3
671	Evaluation of p53 and Its Target Gene Expression as Potential Biomarkers of Cholangiocarcinoma in Thai Patients. <i>Asian Pacific Journal of Cancer Prevention</i> , 2020, 21, 791-798.	0.5	7
672	A deep molecular response of splenic marginal zone lymphoma to front-line checkpoint blockade. <i>Haematologica</i> , 2021, 106, 651-654.	1.7	4
673	Zanubrutinib monotherapy for patients with treatment-naïve chronic lymphocytic leukemia and 17p deletion. <i>Haematologica</i> , 2021, 106, 2354-2363.	1.7	62
674	Novel Interplay between p53 and HO-1 in Embryonic Stem Cells. <i>Cells</i> , 2021, 10, 35.	1.8	8
675	Adaptation to Endoplasmic Reticulum Stress Enhances Resistance of Oral Cancer Cells to Cisplatin by Up-Regulating Polymerase β and Increasing DNA Repair Efficiency. <i>International Journal of Molecular Sciences</i> , 2021, 22, 355.	1.8	11

#	ARTICLE	IF	CITATIONS
676	Serine, glycine and one-carbon metabolism in cancer (Review). <i>International Journal of Oncology</i> , 2020, 58, 158-170.	1.4	68
677	Ailanthone: A novel potential drug for treating human cancer (Review). <i>Oncology Letters</i> , 2020, 20, 1489-1503.	0.8	15
678	Exosomes isolated from CAPS1-overexpressing colorectal cancer cells promote cell migration. <i>Oncology Reports</i> , 2019, 42, 2528-2536.	1.2	13
679	Hitting pause on the cell cycle. <i>ELife</i> , 2019, 8, .	2.8	4
680	Roles of C/EBP class bZip proteins in the growth and cell competition of Rp (<i>Minute</i> TM) mutants in <i>Drosophila</i> . <i>ELife</i> , 2020, 9, .	2.8	37
682	Glioma: molecular signature and crossroads with tumor microenvironment. <i>Cancer and Metastasis Reviews</i> , 2022, 41, 53-75.	2.7	63
683	The ponatinib/gossypol novel combination provides enhanced anticancer activity against murine solid Ehrlich carcinoma via triggering apoptosis and inhibiting proliferation/angiogenesis. <i>Toxicology and Applied Pharmacology</i> , 2021, 432, 115767.	1.3	6
684	Repression of p53 function by SIRT5-mediated desuccinylation at Lysine 120 in response to DNA damage. <i>Cell Death and Differentiation</i> , 2022, 29, 722-736.	5.0	29
685	Genomic abnormalities of TP53 define distinct risk groups of paediatric B-cell non-Hodgkin lymphoma. <i>Leukemia</i> , 2022, 36, 781-789.	3.3	20
686	Effect of p53 and its N-terminally truncated isoform, $\Delta 40p53$, on breast cancer migration and invasion. <i>Molecular Oncology</i> , 2022, 16, 447-465.	2.1	15
687	H2AFZ Is a Prognostic Biomarker Correlated to TP53 Mutation and Immune Infiltration in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 701736.	1.3	17
688	Altered Expression of Shorter p53 Family Isoforms Can Impact Melanoma Aggressiveness. <i>Cancers</i> , 2021, 13, 5231.	1.7	19
689	At a Crossroads to Cancer: How p53-Induced Cell Fate Decisions Secure Genome Integrity. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10883.	1.8	30
690	Multi-Omics Interpretation of Anti-Aging Mechanisms for ω -3 Fatty Acids. <i>Genes</i> , 2021, 12, 1691.	1.0	3
691	Epstein-Barr virus infection mediated TP53 and Bcl-2 expression in nasopharyngeal carcinoma pathogenesis. <i>Molecular and Clinical Oncology</i> , 2021, 15, 260.	0.4	1
692	No apparent p53 activation in CRISPR-engineered gene-edited rabbits. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 10313-10317.	1.6	2
693	Differential Transcriptional Regulation of Polymorphic p53 Codon 72 in Metabolic Pathways. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10793.	1.8	3
694	Shift in MSL1 alternative polyadenylation in response to DNA damage protects cancer cells from chemotherapeutic agent-induced apoptosis. <i>Cell Reports</i> , 2021, 37, 109815.	2.9	13

#	ARTICLE	IF	CITATIONS
695	Micronutrient imbalance and common phenotypes in neural tube defects. <i>Genesis</i> , 2021, 59, e23455.	0.8	14
696	Combination therapy with miR-34a and doxorubicin synergistically induced apoptosis in T-cell acute lymphoblastic leukemia cell line. <i>Medical Oncology</i> , 2021, 38, 142.	1.2	8
697	TP53 in Acute Myeloid Leukemia: Molecular Aspects and Patterns of Mutation. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10782.	1.8	25
698	Regulation of Chemosensitivity in Human Medulloblastoma Cells by p53 and the PI3 Kinase Signaling Pathway. <i>Molecular Cancer Research</i> , 2022, 20, 114-126.	1.5	11
699	Cylindrospermopsin impairs vascular smooth muscle cells by P53-mediated apoptosis due to ROS overproduction. <i>Toxicology Letters</i> , 2021, 353, 83-92.	0.4	6
700	IKK β mediates UVB-induced cell apoptosis by regulating p53 pathway activation. <i>Ecotoxicology and Environmental Safety</i> , 2021, 227, 112892.	2.9	9
711	p53 defies convention again: a p53 mutant that has lost tumor suppression but still can kill. <i>EMBO Journal</i> , 2019, 38, e103322.	3.5	1
714	Methylation of bone morphogenetic protein 2 is associated with poor prognosis in colorectal cancer. <i>Oncology Letters</i> , 2020, 19, 229-238.	0.8	5
718	Extracts of <i>Bridelia ovata</i> and <i>Croton oblongifolius</i> induce apoptosis in human MDA-MB-231 breast cancer cells via oxidative stress and mitochondrial pathways. <i>International Journal of Oncology</i> , 2020, 56, 969-985.	1.4	3
721	Adenosine A1 Receptor Antagonist Up-regulates Casp3 and Stimulates Apoptosis Rate in Breast Cancer Cell Line T47D. <i>International Electronic Journal of Medicine</i> , 2020, 9, 14-20.	0.1	1
724	The Pivotal Role of Senescence in Cell Death and Aging: Where Do We Stand?. <i>Current Molecular Biology Reports</i> , 2020, 6, 91-101.	0.8	0
729	Pharmacogenomics characterization of the MDM2 inhibitor MI-773 reveals candidate tumours and predictive biomarkers. <i>Npj Precision Oncology</i> , 2021, 5, 96.	2.3	2
730	Differential p53-Mediated Cellular Responses to DNA-Damaging Therapeutic Agents. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11828.	1.8	19
731	Discovery of MK-4688: an Efficient Inhibitor of the HDM2-p53 Protein-Protein Interaction. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 16213-16241.	2.9	14
732	Modulation of Long Non-Coding RNAs by Different Classes of Secondary Metabolites from Plants: A Mini-Review on Antitumor Effects. <i>Mini-Reviews in Medicinal Chemistry</i> , 2021, 21, .	1.1	1
733	A Rare Manifestation of a Presumed Non-Osteophilic Brain Neoplasm: Extensive Axial Skeletal Metastases From Glioblastoma With Primitive Neuronal Components. <i>Frontiers in Oncology</i> , 2021, 11, 760697.	1.3	5
734	p53/FBXL20 axis negatively regulates the protein stability of PR55 β , a regulatory subunit of PP2A Ser/Thr phosphatase. <i>Neoplasia</i> , 2021, 23, 1192-1203.	2.3	2
736	The pan-cancer lncRNA MILIP links c-Myc to p53 repression. <i>Molecular and Cellular Oncology</i> , 2021, 8, 1842714.	0.3	2

#	ARTICLE	IF	CITATIONS
738	The <i>p53</i> signaling pathway of the large yellow croaker (<i>Larimichthys crocea</i>) responds to acute cold stress: evidence via spatiotemporal expression analysis of <i>p53</i> , <i>p21</i> , <i>MDM2</i> , <i>IGF-1</i> , <i>Gadd45</i> , <i>Fas</i> , and <i>Akt</i> . <i>PeerJ</i> , 2020, 8, e10532.	0.9	9
739	Diagnostic, Prognostic and Predictive Biomarkers in Gliomas. , 2021, , 43-73.		0
740	Differential requirements for MDM2 E3 activity during embryogenesis and in adult mice. <i>Genes and Development</i> , 2021, 35, 117-132.	2.7	6
741	Loss of TRP53 (p53) accelerates tumorigenesis and changes the tumor spectrum of SJL/J mice. <i>Genes and Cancer</i> , 2020, 11, 83-94.	0.6	2
742	Physical Exercise and Gene p53 – A Mini Review. <i>Journal of Cancer Therapy</i> , 2020, 11, 463-469.	0.1	0
743	Integrative genomic analysis focused on cell cycle genes for MYC-driven aggressive mature B-cell lymphoma. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2020, 60, 87-96.	0.3	1
745	TP53 Combined Phenotype Score Is Associated with the Clinical Outcome of TP53-Mutated Myelodysplastic Syndromes. <i>Cancers</i> , 2021, 13, 5502.	1.7	2
756	Clinical Outcomes of Children With Adrenocortical Carcinoma in the Context of Germline TP53 Status. <i>Journal of Pediatric Hematology/Oncology</i> , 2021, 43, e635-e641.	0.3	7
757	Anti-malarial atovaquone exhibits anti-tumor effects by inducing DNA damage in hepatocellular carcinoma. <i>American Journal of Cancer Research</i> , 2018, 8, 1697-1711.	1.4	11
758	The Short N-Terminal Repeats of Transcription Termination Factor 1 Contain Semi-Redundant Nucleolar Localization Signals and P19-ARF Tumor Suppressor Binding Sites. <i>Yale Journal of Biology and Medicine</i> , 2019, 92, 385-396.	0.2	2
759	Discovery and characterization of a novel splice variant of the p53 tumor suppressor gene in a human T cell leukemia cellline. <i>International Journal of Clinical and Experimental Pathology</i> , 2020, 13, 1121-1135.	0.5	0
761	Carcinogenesis: Mechanisms and Evaluation. , 2022, , 205-254.		3
762	The molecular mechanisms of ferroptosis and its role in cardiovascular disease. <i>Biomedicine and Pharmacotherapy</i> , 2022, 145, 112423.	2.5	57
763	Common Genomic Aberrations in Mouse and Human Breast Cancers with Concurrent P53 Deficiency and Activated PTEN-PI3K-AKT Pathway. <i>International Journal of Biological Sciences</i> , 2022, 18, 229-241.	2.6	2
764	Interference of p53:Twist1 interaction through competing nanobodies. <i>International Journal of Biological Macromolecules</i> , 2022, 194, 24-31.	3.6	4
765	Akt inhibitor augments anti-proliferative efficacy of a dual mTORC1/2 inhibitor by FOXO3a activation in p53 mutated hepatocarcinoma cells. <i>Cell Death and Disease</i> , 2021, 12, 1073.	2.7	9
766	In Situ Sprayed Starvation/Chemodynamic Therapeutic Gel for Post-Surgical Treatment of IDH1 (R132H) Glioma. <i>Advanced Materials</i> , 2022, 34, e2103980.	11.1	67
767	Role of Senescence and Aging in SARS-CoV-2 Infection and COVID-19 Disease. <i>Cells</i> , 2021, 10, 3367.	1.8	42

#	ARTICLE	IF	CITATIONS
768	p53: A double-edged sword in tumor ferroptosis. <i>Pharmacological Research</i> , 2022, 177, 106013.	3.1	28
770	TAp63 regulates bone remodeling by modulating the expression of TNFRSF11B/Osteoprotegerin. <i>Cell Cycle</i> , 2021, 20, 2428-2441.	1.3	1
771	O-GlcNAcylation in Chronic Lymphocytic Leukemia and Other Blood Cancers. <i>Frontiers in Immunology</i> , 2021, 12, 772304.	2.2	6
772	<i>TP53</i> Gain-of-Function and Non-Gain-of-Function Mutations Are Differentially Associated With Sidedness-Dependent Prognosis in Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 171-179.	0.8	33
774	Network based analysis identifies TP53m-BRCA1/2wt-homologous recombination proficient (HRP) population with enhanced susceptibility to Vigil immunotherapy. <i>Cancer Gene Therapy</i> , 2022, 29, 993-1000.	2.2	4
775	The Basally Expressed p53-Mediated Homeostatic Function. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 775312.	1.8	14
776	Colletofragarone A2 and Colletoins A-C from a Fungus <i>Colletotrichum</i> sp. Decrease Mutant p53 Levels in Cells. <i>Journal of Natural Products</i> , 2021, 84, 3131-3137.	1.5	5
777	Familial Breast Cancer: Disease Related Gene Mutations and Screening Strategies for Chinese Population. <i>Frontiers in Oncology</i> , 2021, 11, 740227.	1.3	3
778	Senescence in chronic wounds and potential targeted therapies. <i>Burns and Trauma</i> , 2022, 10, tkab045.	2.3	16
779	TP53_PROF: a machine learning model to predict impact of missense mutations in <i>TP53</i> . <i>Briefings in Bioinformatics</i> , 2022, 23, .	3.2	9
780	Juvenile trabecular ossifying fibroma: Immunohistochemical expression of MDM2, CDK4 and p53 compared to conventional ossifying fibroma. <i>Journal of Clinical and Experimental Dentistry</i> , 2022, 14, e27-e34.	0.5	2
782	Potential of rescue and reactivation of tumor suppressor p53 for cancer therapy. <i>Biophysical Reviews</i> , 2022, 14, 267-275.	1.5	9
783	Highly sensitive and quantitative biodetection with lipid-polymer hybrid nanoparticles having organic room-temperature phosphorescence. <i>Biosensors and Bioelectronics</i> , 2022, 199, 113889.	5.3	8
784	Analysis of proliferation and apoptosis, MUC-1 and Cdx-2 expression in distal colonic polyps. <i>Morphologia</i> , 2020, 14, 124-131.	0.1	0
785	Mutation Analysis and Single Nucleotide Polymorphism of TP53 Gene in Breast Cancer in East Java. <i>Journal of Tropical Life Science</i> , 2021, 11, 361-366.	0.1	0
786	LncRNAs, the Molecules Involved in Communications With Colorectal Cancer Stem Cells. <i>Frontiers in Oncology</i> , 2022, 12, 811374.	1.3	4
787	Role of p53 in Human Cancers. , 0, , .		1
788	It's Getting Complicated—A Fresh Look at p53-MDM2-ARF Triangle in Tumorigenesis and Cancer Therapy. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 818744.	1.8	15

#	ARTICLE	IF	CITATIONS
789	p27, The Cell Cycle and Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1211.	1.8	15
790	Fasting improves therapeutic response in hepatocellular carcinoma through p53-dependent metabolic synergism. <i>Science Advances</i> , 2022, 8, eabh2635.	4.7	35
791	SPARCLE, a p53-induced lncRNA, controls apoptosis after genotoxic stress by promoting PARP-1 cleavage. <i>Molecular Cell</i> , 2022, 82, 785-802.e10.	4.5	24
792	HELLS Is Negatively Regulated by Wild-Type P53 in Liver Cancer by a Mechanism Involving P21 and FOXM1. <i>Cancers</i> , 2022, 14, 459.	1.7	6
793	Mutant p53 reactivator SLMP53-2 hinders ultraviolet B radiation-induced skin carcinogenesis. <i>Pharmacological Research</i> , 2022, 175, 106026.	3.1	3
794	Wild-type p53 suppresses formin-binding protein-17 (FBP17) to reduce invasion. <i>Carcinogenesis</i> , 2022, 43, 494-503.	1.3	4
796	Reciprocal modulation of long noncoding RNA EMS and p53 regulates tumorigenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	6
797	Acquisition of taxane resistance by p53 inactivation in ovarian cancer cells. <i>Acta Pharmacologica Sinica</i> , 2022, , .	2.8	4
798	A prediction model integrated genomic alterations and immune signatures of tumor immune microenvironment for early recurrence of stage I NSCLC after curative resection. <i>Translational Lung Cancer Research</i> , 2022, 11, 24-42.	1.3	5
799	p53 in ferroptosis regulation: the new weapon for the old guardian. <i>Cell Death and Differentiation</i> , 2022, 29, 895-910.	5.0	193
800	Mesenchymal Stem/Stromal Cell Senescence: Hallmarks, Mechanisms, and Combating Strategies. <i>Stem Cells Translational Medicine</i> , 2022, 11, 356-371.	1.6	62
801	Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c). <i>Blood Cancer Journal</i> , 2022, 12, 5.	2.8	49
802	RBL2/DREAM-mediated repression of the Aurora kinase A/B pathway determines therapy responsiveness and outcome in p53 WT NSCLC. <i>Scientific Reports</i> , 2022, 12, 1049.	1.6	8
803	Small-Molecule NSC59984 Induces Mutant p53 Degradation through a ROS-ERK2-MDM2 Axis in Cancer Cells. <i>Molecular Cancer Research</i> , 2022, 20, 622-636.	1.5	13
804	Mechanistic insight into the destabilization of p53TD tetramer by cancer-related R337H mutation: a molecular dynamics study. <i>Physical Chemistry Chemical Physics</i> , 2022, 24, 5199-5210.	1.3	3
805	Autophagy Contributes to Metabolic Reprogramming and Therapeutic Resistance in Pancreatic Tumors. <i>Cells</i> , 2022, 11, 426.	1.8	17
806	Comparison of acute myeloid leukemia and myelodysplastic syndromes with TP53 aberrations. <i>Annals of Hematology</i> , 2022, 101, 837-846.	0.8	5
807	Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome. <i>Blood</i> , 2022, 139, 2347-2354.	0.6	131

#	ARTICLE	IF	CITATIONS
809	Deletion of Wild-type p53 Facilitates Bone Metastatic Function by Blocking the AIP4 Mediated Ligand-Induced Degradation of CXCR4. <i>Frontiers in Pharmacology</i> , 2021, 12, 792293.	1.6	2
810	A tiered approach to investigate the inhalation toxicity of cobalt substances. Tier 2: Reactive cobalt substances induce oxidative stress in ToxTracker and activate hypoxia target genes. <i>Regulatory Toxicology and Pharmacology</i> , 2022, 129, 105120.	1.3	6
811	Significance of p53 overexpression in the prediction of the malignant transformation risk of oral potentially malignant disorders: A systematic review and meta-analysis. <i>Oral Oncology</i> , 2022, 126, 105734.	0.8	23
812	Metformin bicarbonate-mediated efficient RNAi for precise targeting of TP53 deficiency in colon and rectal cancers. <i>Nano Today</i> , 2022, 43, 101406.	6.2	8
813	p53 mutations define the chromatin landscape to confer drug tolerance in pancreatic cancer. <i>Molecular Oncology</i> , 2022, 16, 1259-1271.	2.1	9
814	Combining p53 mRNA nanotherapy with immune checkpoint blockade reprograms the immune microenvironment for effective cancer therapy. <i>Nature Communications</i> , 2022, 13, 758.	5.8	94
815	The Expression of TP53-Induced Glycolysis and Apoptosis Regulator (TIGAR) Can Be Controlled by the Antioxidant Orchestrator NRF2 in Human Carcinoma Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1905.	1.8	4
816	Therapeutic potential of p53 reactivation in prostate cancer: Strategies and opportunities. <i>European Journal of Pharmacology</i> , 2022, 919, 174807.	1.7	17
817	Key biological mechanisms involved in high-LET radiation therapies with a focus on DNA damage and repair. <i>Expert Reviews in Molecular Medicine</i> , 2022, 24, e15.	1.6	21
818	Cancer mutation profiles predict ICIs efficacy in patients with non-small cell lung cancer. <i>Expert Reviews in Molecular Medicine</i> , 2022, 24, e16.	1.6	1
819	TP53 promotes lineage commitment of human embryonic stem cells through ciliogenesis and sonic hedgehog signaling. <i>Cell Reports</i> , 2022, 38, 110395.	2.9	17
820	Primary cardiac undifferentiated pleomorphic sarcoma is associated with TP53 mutation during lack of MDM2 amplification, and targeted sequencing analysis reveals potentially actionable targets. <i>Human Pathology</i> , 2022, , .	1.1	1
821	Base editing sensor libraries for high-throughput engineering and functional analysis of cancer-associated single nucleotide variants. <i>Nature Biotechnology</i> , 2022, 40, 862-873.	9.4	44
824	Enterobacteria impair host p53 tumor suppressor activity through mRNA destabilization. <i>Oncogene</i> , 2022, 41, 2173-2186.	2.6	4
825	Novel treatments for myelofibrosis: beyond JAK inhibitors. <i>International Journal of Hematology</i> , 2022, 115, 645-658.	0.7	5
826	Etoposide-induced DNA damage is increased in p53 mutants: identification of ATR and other genes that influence effects of p53 mutations on Top2-induced cytotoxicity. <i>Oncotarget</i> , 2022, 13, 332-346.	0.8	9
827	The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy. <i>Cancers</i> , 2022, 14, 1143.	1.7	23
828	Should mutant TP53 be targeted for cancer therapy?. <i>Cell Death and Differentiation</i> , 2022, 29, 911-920.	5.0	47

#	ARTICLE	IF	CITATIONS
829	Integrative Proteome and Ubiquitinome Analyses Reveal the Substrates of BTBD9 and Its Underlying Mechanism in Sleep Regulation. ACS Omega, 2022, 7, 11839-11852.	1.6	3
831	Cytogenetics in Chronic Lymphocytic Leukemia: ERIC Perspectives and Recommendations. HemaSphere, 2022, 6, e707.	1.2	17
832	Zebrafish imaging reveals TP53 mutation switching oncogene-induced senescence from suppressor to driver in primary tumorigenesis. Nature Communications, 2022, 13, 1417.	5.8	11
833	Partial p53 reactivation is sufficient to induce cancer regression. Journal of Experimental and Clinical Cancer Research, 2022, 41, 80.	3.5	11
834	Ferroptosis and Its Potential Role in the Nervous System Diseases. Journal of Inflammation Research, 2022, Volume 15, 1555-1574.	1.6	32
835	p53 regulation by ubiquitin and ubiquitin-like modifications. Genome Instability & Disease, 2022, 3, 179-198.	0.5	2
836	Flow cytometric single cell-based assay to simultaneously detect cell death, cell cycling, DNA content and cell senescence. Cell Death and Differentiation, 2022, 29, 1004-1012.	5.0	5
837	Compound cellular stress maximizes apoptosis independently of p53 in glioblastoma. Cell Cycle, 2022, , 1-13.	1.3	2
838	Foundations of plasmas for medical applications. Plasma Sources Science and Technology, 2022, 31, 054002.	1.3	43
839	Discovery of a New CaMKII-Targeted Synthetic Lethal Therapy against Glioblastoma Stem-like Cells. Cancers, 2022, 14, 1315.	1.7	10
840	Induction of an immortalized songbird cell line allows for gene characterization and knockout by CRISPR-Cas9. Scientific Reports, 2022, 12, 4369.	1.6	5
842	Mutant p53: it's not all one and the same. Cell Death and Differentiation, 2022, 29, 983-987.	5.0	63
843	Rapid recruitment of p53 to DNA damage sites directs DNA repair choice and integrity. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2113233119.	3.3	39
844	TP53/BRAF mutation as an aid in predicting response to immune-checkpoint inhibitor across multiple cancer types. Aging, 2022, 14, 2868-2879.	1.4	0
845	Advanced Strategies for Therapeutic Targeting of Wild-Type and Mutant p53 in Cancer. Biomolecules, 2022, 12, 548.	1.8	21
846	Suppression of p53 response by targeting p53-Mediator binding with a stapled peptide. Cell Reports, 2022, 39, 110630.	2.9	5
847	TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia. Blood, 2022, 140, 58-72.	0.6	46
848	Alternatively mechanistic insights into acetylation in p53-mediated transcriptional regulation of cancer cell-intrinsic PD-1. Fundamental Research, 2023, 3, 647-654.	1.6	0

#	ARTICLE	IF	CITATIONS
849	Genetic Deficiency of p53 Leads to Structural, Functional, and Synaptic Deficits in Primary Somatosensory Cortical Neurons of Adult Mice. <i>Frontiers in Molecular Neuroscience</i> , 2022, 15, 871974.	1.4	4
851	Mesenchymal and stem-like prostate cancer linked to therapy-induced lineage plasticity and metastasis. <i>Cell Reports</i> , 2022, 39, 110595.	2.9	25
852	Poly(C)-binding Protein 2 Regulates the p53 Expression via Interactions with the 5'â€²-Terminal Region of p53 mRNA. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13306.	1.8	6
854	Cytoplasmic innate immune sensing by the caspase-4 non-canonical inflammasome promotes cellular senescence. <i>Cell Death and Differentiation</i> , 2022, 29, 1267-1282.	5.0	14
856	Sex- and Mutation-Specific p53 Gain-of-Function Activity in Gliomagenesis. <i>Cancer Research Communications</i> , 2021, 1, 148-163.	0.7	6
857	Ferroptosis: Can Iron be the Last or Cure for a Cell?. <i>Biochemistry</i> , 0, , .	0.8	0
858	Endoderm development requires centrioles to restrain p53-mediated apoptosis in the absence of ERK activity. <i>Developmental Cell</i> , 2021, 56, 3334-3348.e6.	3.1	9
859	Co-existing TP53 and ARID1A mutations promote aggressive endometrial tumorigenesis. <i>PLoS Genetics</i> , 2021, 17, e1009986.	1.5	24
860	Unravelling undifferentiated soft tissue sarcomas: insights from genomics. <i>Histopathology</i> , 2022, 80, 109-121.	1.6	3
861	Nucleolar Stress Functions Upstream to Stimulate Expression of Autophagy Regulators. <i>Cancers</i> , 2021, 13, 6220.	1.7	7
862	The multifunctional protein E4F1 links P53 to lipid metabolism in adipocytes. <i>Nature Communications</i> , 2021, 12, 7037.	5.8	15
863	Rigosertib and Cholangiocarcinoma: A Cell Cycle Affair. <i>International Journal of Molecular Sciences</i> , 2022, 23, 213.	1.8	3
864	In silico analysis prediction of HepTH1-5 as a potential therapeutic agent by targeting tumour suppressor protein networks. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 1141-1167.	2.0	0
865	Structural and functional characterisation of HepTH1-5 peptide as a potential hepcidin replacement. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 681-704.	2.0	3
866	The dominant TP53 hotspot mutation in <i>IDH</i>-mutant astrocytoma, R273C, has distinctive pathologic features and sex-specific prognostic implications. <i>Neuro-Oncology Advances</i> , 2022, 4, vdab182.	0.4	5
867	Impact of cancer cell-intrinsic features on neutrophil behavior. <i>Seminars in Immunology</i> , 2021, 57, 101546.	2.7	9
868	Metabolic regulation of somatic stem cells in vivo. <i>Nature Reviews Molecular Cell Biology</i> , 2022, 23, 428-443.	16.1	35
869	Ferroptosis Biology and Implication in Cancers. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 892957.	1.6	15

#	ARTICLE	IF	CITATIONS
870	Abrogating the Interaction Between p53 and Mortalin (Grp75/HSPA9/mtHsp70) for Cancer Therapy: The Story so far. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 879632.	1.8	7
871	p53 alters intracellular Ca ²⁺ signaling through regulation of TRPM4. <i>Cell Calcium</i> , 2022, 104, 102591.	1.1	7
873	Targeting TP53-Mutated Acute Myeloid Leukemia: Research and Clinical Developments. <i>OncoTargets and Therapy</i> , 2022, Volume 15, 423-436.	1.0	14
874	Identification of environmental chemicals that activate p53 signaling after in vitro metabolic activation. <i>Archives of Toxicology</i> , 2022, 96, 1975-1987.	1.9	10
875	Temporal Bone Squamous Cell Carcinoma: Molecular Markers Involved in Carcinogenesis, Behavior, and Prognosis: A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4536.	1.8	3
876	LncRNA, miRNA and transcriptional co-regulatory network of breast and ovarian cancer reveals hub molecules. <i>Meta Gene</i> , 2022, , 101024.	0.3	0
877	Stapled peptides as scaffolds for developing radiotracers for intracellular targets: Preliminary evaluation of a radioiodinated MDM2-binding stapled peptide in the SJS-1 osteosarcoma model. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2022, 66, 128725.	1.0	1
894	The Somatic Mutational Landscape and Role of ARID1A Gene in Hepatocellular Carcinoma. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
895	Post-translational Modifications of the p53 Protein and the Impact in Alzheimer's Disease: A Review of the Literature. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 835288.	1.7	11
896	The E3 Ubiquitin Ligase Fbxo4 Functions as a Tumor Suppressor: Its Biological Importance and Therapeutic Perspectives. <i>Cancers</i> , 2022, 14, 2133.	1.7	4
897	Correlation of Ferroptosis and Other Types of Cell Death in Neurodegenerative Diseases. <i>Neuroscience Bulletin</i> , 2022, 38, 938-952.	1.5	18
898	Association Between the TP53 Polymorphisms and Breast Cancer Risk: An Updated Meta-Analysis. <i>Frontiers in Genetics</i> , 2022, 13, 807466.	1.1	3
899	Relationship between Telomere Length, TERT Genetic Variability and TERT, TP53, SP1, MYC Gene Co-Expression in the Clinicopathological Profile of Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5164.	1.8	9
900	The Complex Interaction between P53 and miRNAs Joins New Awareness in Physiological Stress Responses. <i>Cells</i> , 2022, 11, 1631.	1.8	6
901	Suppression of the Proliferation of Huh7 Hepatoma Cells Involving the Downregulation of Mutant p53 Protein and Inactivation of the STAT 3 Pathway with Ailanthoidol. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5102.	1.8	5
902	Reverting TP53 Mutation in Breast Cancer Cells: Prime Editing Workflow and Technical Considerations. <i>Cells</i> , 2022, 11, 1612.	1.8	7
903	The p53 Transactivation Domain 1-Dependent Response to Acute DNA Damage in Endothelial Cells Protects against Radiation-Induced Cardiac Injury. <i>Radiation Research</i> , 2022, 198, .	0.7	0
904	The Mettl3 epitranscriptomic writer amplifies p53 stress responses. <i>Molecular Cell</i> , 2022, 82, 2370-2384.e10.	4.5	22

#	ARTICLE	IF	CITATIONS
905	Exosome-transmitted miR-769-5p confers cisplatin resistance and progression in gastric cancer by targeting CASP9 and promoting the ubiquitination degradation of p53. <i>Clinical and Translational Medicine</i> , 2022, 12, e780.	1.7	24
906	Multiple myeloma with high-risk cytogenetics and its treatment approach. <i>International Journal of Hematology</i> , 2022, 115, 762-777.	0.7	30
907	Opposing roles of HDAC6 in liver regeneration and hepatocarcinogenesis. <i>Cancer Science</i> , 2022, 113, 2311-2322.	1.7	5
908	Establishment of tumor protein p53 mutation-based prognostic signatures for acute myeloid leukemia. <i>Current Research in Translational Medicine</i> , 2022, 70, 103347.	1.2	0
909	Molecular docking analysis of p53 with Toll-like receptors. <i>Bioinformatics</i> , 2021, 17, 784-789.	0.2	3
910	Mammalian eIF4E2-GSK3 β maintains basal phosphorylation of p53 to resist senescence under hypoxia. <i>Cell Death and Disease</i> , 2022, 13, 459.	2.7	0
911	Signaling Pathway Reporter Screen with SARS-CoV-2 Proteins Identifies nsp5 as a Repressor of p53 Activity. <i>Viruses</i> , 2022, 14, 1039.	1.5	12
912	Estradiol-mediated inhibition of DNMT1 decreases p53 expression to induce M2-macrophage polarization in lung cancer progression. <i>Oncogenesis</i> , 2022, 11, 25.	2.1	12
913	Tumor suppressor p53 restrains cancer cell dissemination by modulating mitochondrial dynamics. <i>Oncogenesis</i> , 2022, 11, 26.	2.1	10
914	The interaction of and DNA repair gene mutations and their impact on tumor mutation burden and immune response in human malignancies.. <i>American Journal of Cancer Research</i> , 2022, 12, 1866-1883.	1.4	0
915	Cellular and molecular mechanisms of plasticity in cancer. <i>Trends in Cancer</i> , 2022, 8, 735-746.	3.8	24
917	Stressing the Regulatory Role of Long Non-Coding RNA in the Cellular Stress Response during Cancer Progression and Therapy. <i>Biomedicines</i> , 2022, 10, 1212.	1.4	3
918	Complementary omics strategies to dissect p53 signaling networks under nutrient stress. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, .	2.4	4
919	Post-Translational Modifications of p53 in Ferroptosis: Novel Pharmacological Targets for Cancer Therapy. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	9
922	Exploring the metabolic landscape of pancreatic ductal adenocarcinoma cells using genome-scale metabolic modeling. <i>IScience</i> , 2022, 25, 104483.	1.9	4
923	Identification of Hub Genes Associated With the Development of Stomach Adenocarcinoma by Integrated Bioinformatics Analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
924	Association of Nucleostemin Polymorphisms with Chronic Hepatitis B Virus Infection in Chinese Han Population. <i>Genetic Testing and Molecular Biomarkers</i> , 2022, 26, 255-262.	0.3	1
925	MDM2 binds and ubiquitinates PARP1 to enhance DNA replication fork progression. <i>Cell Reports</i> , 2022, 39, 110879.	2.9	13

#	ARTICLE	IF	CITATIONS
926	Translation of Cellular Senescence to Novel Therapeutics: Insights From Alternative Tools and Models. <i>Frontiers in Aging</i> , 2022, 3, .	1.2	4
928	Red Light Phototherapy Using Light-Emitting Diodes Inhibits Melanoma Proliferation and Alters Tumor Microenvironments. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	8
929	p53 and Its Isoforms in Renal Cell Carcinoma—Do They Matter?. <i>Biomedicines</i> , 2022, 10, 1330.	1.4	2
931	Crosstalk between ferroptosis and stress—Implications in cancer therapeutic responses. , 2022, 1, 92-113.		4
932	Clinical significance of chromosomal integrity in gastric cancers. <i>International Journal of Biological Markers</i> , 0, , 039361552211062.	0.7	1
933	A common pathway to cancer: Oncogenic mutations abolish p53 oscillations. <i>Progress in Biophysics and Molecular Biology</i> , 2022, , .	1.4	2
934	Research trends and hotspots on human papillomavirus: a bibliometric analysis of 100 most-cited articles. <i>Annals of Translational Medicine</i> , 2022, .	0.7	1
935	Converging Mechanisms of Epileptogenesis and Their Insight in Glioblastoma. <i>Frontiers in Molecular Neuroscience</i> , 0, 15, .	1.4	9
936	Murine Models of Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
937	Telomeric 8-oxo-guanine drives rapid premature senescence in the absence of telomere shortening. <i>Nature Structural and Molecular Biology</i> , 2022, 29, 639-652.	3.6	35
938	Virus-Mediated Inhibition of Apoptosis in the Context of EBV-Associated Diseases: Molecular Mechanisms and Therapeutic Perspectives. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7265.	1.8	8
940	Chronic restraint stress promotes gastric epithelial malignant transformation by activating the Akt/p53 signaling pathway via ADRB2. <i>Oncology Letters</i> , 2022, 24, .	0.8	2
941	Field exposure to 50ÂHz significantly affects wild-type and unfolded p53 expression in NB69 neuroblastoma cells. <i>Oncology Letters</i> , 2022, 24, .	0.8	0
942	Efficient Correction of Oncogenic <i>KRAS</i> and <i>TP53</i> Mutations through CRISPR Base Editing. <i>Cancer Research</i> , 2022, 82, 3002-3015.	0.4	12
943	Exonucleases: Degrading DNA to Deal with Genome Damage, Cell Death, Inflammation and Cancer. <i>Cells</i> , 2022, 11, 2157.	1.8	6
944	Co-dependencies in the tumor immune microenvironment. <i>Oncogene</i> , 2022, 41, 3821-3829.	2.6	8
945	Noncoding RNAs as sensors of tumor microenvironmental stress. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	8
946	Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination Therapies. <i>Cancers</i> , 2022, 14, 3456.	1.7	18

#	ARTICLE	IF	CITATIONS
948	A p53â€“phosphoinositide signalosome regulates nuclear AKT activation. <i>Nature Cell Biology</i> , 2022, 24, 1099-1113.	4.6	26
949	Benign SNPs in the Coding Region of <i>TP53</i>: Finding the Needles in a Haystack of Pathogenic Variants. <i>Cancer Research</i> , 2022, 82, 3420-3431.	0.4	6
950	Computational analysis uncovers the deleterious SNPs along with the mutational spectrum of p53 gene and its differential expression pattern in pan-cancer. <i>Bulletin of the National Research Centre</i> , 2022, 46, .	0.7	0
951	APR-246 triggers ferritinophagy and ferroptosis of diffuse large B-cell lymphoma cells with distinct TP53 mutations. <i>Leukemia</i> , 2022, 36, 2269-2280.	3.3	23
952	19q13.12 KRAB zinc-finger protein ZNF383 represses p53 signaling pathway by interacting with p53. <i>Cellular Signalling</i> , 2022, 98, 110405.	1.7	0
953	Cancer Biology and Implications for the Perioperative Period. , 2023, , 24-45.		1
954	Structural Basis of Mutation-Dependent p53 Tetramerization Deficiency. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7960.	1.8	1
955	The repression of oncoprotein SET by the tumor suppressor p53 reveals a p53-SET-PP2A feedback loop for cancer therapy. <i>Science China Life Sciences</i> , 2023, 66, 81-93.	2.3	1
956	The Role of Sestrins in the Regulation of the Cellular Response to Stress. <i>Biology Bulletin Reviews</i> , 2022, 12, 347-364.	0.3	0
958	In Pursuit of Genetic Prognostic Factors and Treatment Approaches in Secondary Acute Myeloid Leukemiaâ€“A Narrative Review of Current Knowledge. <i>Journal of Clinical Medicine</i> , 2022, 11, 4283.	1.0	0
960	Therapeutic restoring p53 function with small molecule for oncogene-driven non-small cell lung cancer by targeting serine 392 phosphorylation. <i>Biochemical Pharmacology</i> , 2022, 203, 115188.	2.0	3
961	Cell Division/Death: Cell Cycle â€“ The Restriction Point. , 2022, , .		0
962	Mechanism and application of nonessential amino acid deprivation associated with tumor therapy. , 2022, 1, .		2
963	An Updated View of the Roles of p53 in Embryonic Stem Cells. <i>Stem Cells</i> , 2022, 40, 883-891.	1.4	8
964	Boosting Antitumor Immunity with an Expanded Neoepitope Landscape. <i>Cancer Research</i> , 2022, 82, 3637-3649.	0.4	4
965	The development and validation of a novel senescence-related long-chain non-coding RNA (lncRNA) signature that predicts prognosis and the tumor microenvironment of patients with hepatocellular carcinoma. <i>Annals of Translational Medicine</i> , 2022, 10, 766-766.	0.7	4
966	Decreased DNA Damage and Improved p53 Specificity of RITA Analogs. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 1524-1534.	1.9	1
967	Current state of knowledge of human DNA polymerase eta protein structure and disease-causing mutations. <i>Mutation Research - Reviews in Mutation Research</i> , 2022, 790, 108436.	2.4	6

#	ARTICLE	IF	CITATIONS
968	Structural studies of antitumor compounds that target the <sc>RING</sc> domain of <sc>MDM2</sc>. Protein Science, 2022, 31, .	3.1	0
969	Comprehensive analysis of pyroptotic gene prognostic signatures associated with tumor immune microenvironment and genomic mutation in breast cancer. Frontiers in Immunology, 0, 13, .	2.2	4
970	Colletofragarone A2 Inhibits Cancer Cell Growth <i>In Vivo</i> and Leads to the Degradation and Aggregation of Mutant p53. Chemical Research in Toxicology, 2022, 35, 1598-1603.	1.7	3
971	MYCN and Metabolic Reprogramming in Neuroblastoma. Cancers, 2022, 14, 4113.	1.7	15
972	Preclinical findings reveal the pharmacological targets of ferulic acid in the treatment of traumatic brain injury. Food Science and Nutrition, 2022, 10, 4403-4410.	1.5	2
973	Somatic compensation of inherited bone marrow failure. Seminars in Hematology, 2022, 59, 167-173.	1.8	3
974	Impact of TP53 Mutations on EGFR-Tyrosine Kinase Inhibitor Efficacy and Potential Treatment Strategy. Clinical Lung Cancer, 2023, 24, 29-39.	1.1	6
975	Association of TP53 rs1042522 C<sup>t>G Polymorphism with Glioma Risk in Chinese Children. BioMed Research International, 2022, 2022, 1-6.	0.9	2
976	Ordered and deterministic cancer genome evolution after p53 loss. Nature, 2022, 608, 795-802.	13.7	90
978	Knockdown of RRM1 in tumor cells promotes radio-/chemotherapy induced ferroptosis by regulating p53 ubiquitination and p21-GPX4 signaling axis. Cell Death Discovery, 2022, 8, .	2.0	12
981	Protein of a thousand faces: The tumor-suppressive and oncogenic responses of p53. Frontiers in Molecular Biosciences, 0, 9, .	1.6	9
982	Cellular senescence and abdominal aortic aneurysm: From pathogenesis to therapeutics. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	2
983	EXABS-100-AML Is TP53 Mutated AML the Same Disease as TP53 Mutated MDS?. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, S3-S5.	0.2	0
984	O-GlcNAc transferase is important for homology-directed repair. DNA Repair, 2022, 119, 103394.	1.3	7
985	Aberrant transcription factors in the cancers of the pancreas. Seminars in Cancer Biology, 2022, 86, 28-45.	4.3	5
986	Synthesis and biological evaluation of novel all-hydrocarbon cross-linked aza-stapled peptides. Organic and Biomolecular Chemistry, 2022, 20, 7963-7971.	1.5	2
987	Extra-Ribosome Functions of Ribosomal Proteins. , 2022, , .		0
988	Druggable sites/pockets of the p53-DNAJA1 protein-protein interaction: In silico modeling and in vitro/in vivo validation. Methods in Enzymology, 2022, , 83-107.	0.4	0

#	ARTICLE	IF	CITATIONS
989	Research Progress of p53 Gene and Tumor. World Journal of Cancer Research, 2022, 12, 147-152.	0.1	0
990	Multiple Myeloma: Bioinformatic Analysis for Identification of Key Genes and Pathways. Bioinformatics and Biology Insights, 2022, 16, 117793222211155.	1.0	3
991	A novel senescence-associated LncRNA signature predicts the prognosis and tumor microenvironment of patients with colorectal cancer: a bioinformatics analysis. Journal of Gastrointestinal Oncology, 2022, 13, 1842-1863.	0.6	4
992	Antitumor effect of <i>Escherichia coli</i> -derived outer membrane vesicles on neuroblastoma <i>in vitro</i> and <i>in vivo</i> . Acta Biochimica Et Biophysica Sinica, 2022, , .	0.9	3
994	Comprehensive bioinformatics analysis reveals the prognostic value, predictive value, and immunological roles of ANLN in human cancers. Frontiers in Genetics, 0, 13, .	1.1	1
995	Downregulated miR-150-5p in the Tissue of Nasopharyngeal Carcinoma. Genetical Research, 2022, 2022, 1-13.	0.3	1
996	Empirical single-cell tracking and cell-fate simulation reveal dual roles of p53 in tumor suppression. ELife, 0, 11, .	2.8	1
999	Ferroptosis in glioma treatment: Current situation, prospects and drug applications. Frontiers in Oncology, 0, 12, .	1.3	4
1000	Regulating the p53 Tumor Suppressor Network at PML Biomolecular Condensates. Cancers, 2022, 14, 4549.	1.7	7
1001	Clonal hematopoiesis, somatic mosaicism, and age-associated disease. Physiological Reviews, 2023, 103, 649-716.	13.1	21
1002	Impact of TP53 mutations in Triple Negative Breast Cancer. Npj Precision Oncology, 2022, 6, .	2.3	9
1003	Increased p53 expression induced by APR-246 reprograms tumor-associated macrophages to augment immune checkpoint blockade. Journal of Clinical Investigation, 2022, 132, .	3.9	4
1005	Oxygen-boosted biomimetic nanoplatform for synergetic phototherapy/ferroptosis activation and reversal of immune-suppressed tumor microenvironment. Biomaterials, 2022, 290, 121832.	5.7	29
1006	A comprehensive review of pancreatic cancer and its therapeutic challenges. Aging, 2022, 14, 7635-7649.	1.4	16
1007	Anti-cancer properties of <i>Caulerpa racemosa</i> by altering expression of Bcl-2, BAX, cleaved caspase 3 and apoptosis in HeLa cancer cell culture. Frontiers in Oncology, 0, 12, .	1.3	6
1008	A sensitive and specific nano-vehicle based on self-amplified dual-input synthetic gene circuit for intracellular imaging and treatment. Biosensors and Bioelectronics, 2022, 218, 114746.	5.3	3
1009	A comprehensive study of p53 protein. Journal of Cellular Biochemistry, 2022, 123, 1891-1937.	1.2	7
1010	Long-term p21 and p53 dynamics regulate the frequency of mitosis events and cell cycle arrest following radiation damage. Cell Death and Differentiation, 0, , .	5.0	2

#	ARTICLE	IF	CITATIONS
1011	Liquid-liquid phase separation: A new perspective to understanding aging and pathogenesis. <i>BioScience Trends</i> , 2022, 16, 359-362.	1.1	3
1012	Glioblastoma multiforme: Diagnosis, treatment, and invasion. <i>Journal of Biomedical Research</i> , 2023, 37, 47.	0.7	1
1013	Rewiring glucose metabolism improves 5-FU efficacy in p53-deficient/KRASG12D glycolytic colorectal tumors. <i>Communications Biology</i> , 2022, 5, .	2.0	5
1014	Nuclear Proteomics of Induced Leukemia Cell Differentiation. <i>Cells</i> , 2022, 11, 3221.	1.8	4
1015	Iron metabolism, ferroptosis, and lncRNA in cancer: knowns and unknowns. <i>Journal of Zhejiang University: Science B</i> , 2022, 23, 844-862.	1.3	17
1016	Phase Separation-Based Biochemical Assays for Biomolecular Interactions. <i>Methods in Molecular Biology</i> , 2023, , 225-236.	0.4	2
1017	Genetic deletion of <i>hspa8</i> leads to selective tissue malformations in zebrafish embryonic development. <i>Journal of Cell Science</i> , 2022, 135, .	1.2	5
1018	Transient regulation of focal adhesion via Tensin3 is required for nascent oligodendrocyte differentiation. <i>ELife</i> , 0, 11, .	2.8	5
1019	A Totipotent α -Cln1 Peptide Sequentially Blocks Immune Checkpoint and Reverses the Immunosuppressive Tumor Microenvironment. <i>Advanced Materials</i> , 2023, 35, .	11.1	10
1020	The molecular mechanisms and targeting strategies of transcription factors in cholangiocarcinoma. <i>Expert Opinion on Therapeutic Targets</i> , 0, , 1-9.	1.5	1
1021	Development and validation of a combined ferroptosis and immune prognostic signature for lung adenocarcinoma. <i>Translational Cancer Research</i> , 2022, 11, 3620-3633.	0.4	2
1022	TP53 Mutation Mapping in Advanced Non-Small Cell Lung Cancer: A Real-World Retrospective Cohort Study. <i>Current Oncology</i> , 2022, 29, 7411-7419.	0.9	4
1024	Current insights into the regulation of programmed cell death by TP53 mutation in cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
1025	Gain of Function (GOF) Mutant p53 in Cancer—Current Therapeutic Approaches. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13287.	1.8	12
1026	<i>MYC</i> and therapy resistance in cancer: risks and opportunities. <i>Molecular Oncology</i> , 2022, 16, 3828-3854.	2.1	20
1027	Drugging p53 in cancer: one protein, many targets. <i>Nature Reviews Drug Discovery</i> , 2023, 22, 127-144.	21.5	151
1028	Detection of TP53 Mutation in Acute Myeloid Leukemia by RT-PCR-Based Sanger Sequencing. <i>Methods in Molecular Biology</i> , 2023, , 87-95.	0.4	2
1029	Germline Testing for Individuals with Pancreatic Adenocarcinoma and Novel Genetic Risk Factors. <i>Hematology/Oncology Clinics of North America</i> , 2022, 36, 943-960.	0.9	0

#	ARTICLE	IF	CITATIONS
1030	Molecular profiling identifies distinct subtypes across TP53 mutant tumors. JCI Insight, 2022, 7, .	2.3	3
1031	Low Expression of p53 in Sacrouterine Ligament as A Risk Factor for Stage III-IV Uterine Prolapse. European Journal of Medical and Health Sciences, 2022, 4, 100-104.	0.1	0
1032	Nutlin-3 suppresses tumorigenesis and progression of oral squamous cell carcinoma and enhances chemosensitivity to cisplatin. Cytotechnology, 0, , .	0.7	0
1034	Feline Oncogenomics: What Do We Know about the Genetics of Cancer in Domestic Cats?. Veterinary Sciences, 2022, 9, 547.	0.6	4
1036	Fusion gene recurrence in non-small cell lung cancers and its association with cigarette smoke exposure. Translational Lung Cancer Research, 2022, 11, 2022-2039.	1.3	1
1038	<scp>APE1</scp> interacts with the nuclear exosome complex protein <scp>MTR4</scp> and is involved in cisplatinâ€and 5â€fluorouracilâ€induced <scp>RNA</scp> damage response. FEBS Journal, 2023, 290, 1740-1764.	2.2	5
1039	Defect in Ser312 phosphorylation of Tp53 dysregulates lipid metabolism for fatty accumulation and fatty liver susceptibility: Revealed by lipidomics. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2022, 1211, 123491.	1.2	0
1040	Single-cell methods in myeloproliferative neoplasms: old questions, new technologies. Blood, 2023, 141, 380-390.	0.6	4
1041	A novel senescence-related lncRNA signature that predicts prognosis and the tumor microenvironment in patients with lung adenocarcinoma. Frontiers in Genetics, 0, 13, .	1.1	3
1042	Metabolic regulation by p53 prevents R-loop-associated genomic instability. Cell Reports, 2022, 41, 111568.	2.9	13
1043	Aerobic glycolysis and tumor progression of hepatocellular carcinoma are mediated by ubiquitin of P53 K48-linked regulated by TRIM37. Experimental Cell Research, 2022, 421, 113377.	1.2	7
1044	Analysis of the p53/microRNA Network in Cancer. Advances in Experimental Medicine and Biology, 2022, , 187-228.	0.8	3
1045	CircANKRD12 Is Induced in Endothelial Cell Response to Oxidative Stress. Cells, 2022, 11, 3546.	1.8	3
1046	Haploidentical haematopoietic stem cell transplantation for TP53â€mutated acute myeloid leukaemia. British Journal of Haematology, 0, , .	1.2	0
1047	Interactions of small molecules with DNA junctions. Nucleic Acids Research, 2022, 50, 12636-12656.	6.5	11
1048	Identification of 3-Phenylquinoline Derivative PQ1 as an Antagonist of p53 Transcriptional Activity. ACS Omega, 0, , .	1.6	0
1049	AGO4 suppresses tumor growth by modulating autophagy and apoptosis via enhancing TRIM21-mediated ubiquitination of GRP78 in a p53-independent manner. Oncogene, 2023, 42, 62-77.	2.6	7
1050	A novel classification of HCC basing on fatty-acid-associated lncRNA. Scientific Reports, 2022, 12, .	1.6	1

#	ARTICLE	IF	CITATIONS
1051	BRCA1 and TP53 codeficiency causes a PARP inhibitor-sensitive erythroproliferative neoplasm. <i>JCI Insight</i> , 2022, 7, .	2.3	0
1052	Immune checkpoint therapy and response biomarkers in non-small-cell lung cancer: Serum NY-ESO-1 and XAGE1 antibody as predictive and monitoring markers. <i>Advances in Clinical Chemistry</i> , 2022, , .	1.8	0
1054	Dynamic behavior of P53-Mdm2-Wip1 gene regulatory network under the influence of time delay and noise. <i>Mathematical Biosciences and Engineering</i> , 2022, 20, 2321-2347.	1.0	0
1055	Insights into Regulators of p53 Acetylation. <i>Cells</i> , 2022, 11, 3825.	1.8	12
1056	Resveratrol induces the production of reactive oxygen species, interferes with the cell cycle, and inhibits the cell migration of bladder tumour cells with different TP53 status. <i>Natural Product Research</i> , 2023, 37, 3838-3843.	1.0	2
1057	BOREAS: a global, phase III study of the MDM2 inhibitor navtemadlin (KRT-232) in relapsed/refractory myelofibrosis. <i>Future Oncology</i> , 2022, 18, 4059-4069.	1.1	10
1058	P53 maintains gallid alpha herpesvirus 1 replication by direct regulation of nucleotide metabolism and ATP synthesis through its target genes. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	1
1059	The Four Homeostasis Knights: In Balance upon Post-Translational Modifications. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14480.	1.8	1
1060	Signaling pathways in cancer-associated fibroblasts: recent advances and future perspectives. <i>Cancer Communications</i> , 2023, 43, 3-41.	3.7	43
1061	TP53-related signature for predicting prognosis and tumor microenvironment characteristics in bladder cancer: A multi-omics study. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	5
1062	Development of a Novel NGS Methodology for Ultrasensitive Circulating Tumor DNA Detection as a Tool for Early-Stage Breast Cancer Diagnosis. <i>International Journal of Molecular Sciences</i> , 2023, 24, 146.	1.8	3
1063	Epitope identification for p53R273C mutant. <i>Immunity, Inflammation and Disease</i> , 2023, 11, .	1.3	0
1064	Recent progress in molecular mechanisms of postoperative recurrence and metastasis of hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 0, 28, 6433-6477.	1.4	7
1065	Tumor Microenvironment and Microvascular Density in Human Glioblastoma. <i>Cells</i> , 2023, 12, 11.	1.8	5
1066	The function of p53 and its role in Alzheimer's and Parkinson's disease compared to age-related macular degeneration. <i>Frontiers in Neuroscience</i> , 0, 16, .	1.4	8
1067	Cell cycle block by p53 activation reduces SARS-CoV-2 release in infected alveolar basal epithelial A549-hACE2 cells. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	7
1068	Unraveling the Structural Changes in the DNA-Binding Region of Tumor Protein p53 (TP53) upon Hotspot Mutation p53 Arg248 by Comparative Computational Approach. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15499.	1.8	3
1069	p53 regulates expression of nuclear envelope components in cancer cells. <i>Biology Direct</i> , 2022, 17, .	1.9	19

#	ARTICLE	IF	CITATIONS
1070	A selective LIS1 requirement for mitotic spindle assembly discriminates distinct T-cell division mechanisms within the T-cell lineage. <i>ELife</i> , 0, 11, .	2.8	0
1071	The mutational spectrum in whole exon of p53 in oral squamous cell carcinoma and its clinical implications. <i>Scientific Reports</i> , 2022, 12, .	1.6	3
1072	Sphingosine Kinase 2 in Stromal Fibroblasts Creates a Hospitable Tumor Microenvironment in Breast Cancer. <i>Cancer Research</i> , 2023, 83, 553-567.	0.4	6
1073	Stages of preadipocyte differentiation: biomarkers and pathways for extracellular structural remodeling. <i>Hereditas</i> , 2022, 159, .	0.5	0
1074	Long non-coding RNA TILR constitutively represses TP53 and apoptosis in lung cancer. <i>Oncogene</i> , 2023, 42, 364-373.	2.6	6
1075	Influence of chain length and branching on poly(ADP-ribose)â€“protein interactions. <i>Nucleic Acids Research</i> , 2023, 51, 536-552.	6.5	4
1076	P53 protein and the diseases in central nervous system. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	2
1077	Transcription factors in the pathogenesis of pulmonary arterial hypertensionâ€“Current knowledge and therapeutic potential. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	0
1078	A role of cytoplasmic p53 in the regulation of metabolism shown by bat-mimicking p53 NLS mutant mice. <i>Cell Reports</i> , 2023, 42, 111920.	2.9	3
1080	Development and Assessment of a Novel Core Biopsy-Based Prediction Model for Pathological Complete Response to Neoadjuvant Chemotherapy in Women with Breast Cancer. <i>International Journal of Environmental Research and Public Health</i> , 2023, 20, 1617.	1.2	1
1081	Germline TP53 mutations undergo copy number gain years prior to tumor diagnosis. <i>Nature Communications</i> , 2023, 14, .	5.8	8
1082	Profilin 1 deficiency drives mitotic defects and reduces genome stability. <i>Communications Biology</i> , 2023, 6, .	2.0	2
1084	New phase therapeutic pursuits for targeted drug delivery in glioblastoma multiforme. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , 866-888.	0.5	0
1085	Characterisation of a novel transcript LNPPS acting as tumour suppressor in bladder cancer via PDCD5â€“mediated p53 degradation blockage. <i>Clinical and Translational Medicine</i> , 2023, 13, .	1.7	1
1086	Rise of the natural red pigment â€“prodigiosinâ€™ as an immunomodulator in cancer. <i>Cancer Cell International</i> , 2022, 22, .	1.8	5
1087	p53 inhibits CTR1-mediated cisplatin absorption by suppressing SP1 nuclear translocation in osteosarcoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
1088	Suicide gene strategies applied in ovarian cancer studies. <i>Cancer Gene Therapy</i> , 2023, 30, 812-821.	2.2	2
1089	Exploring structural determinants and the role of nucleolin in formation of the long-range interaction between untranslated regions of p53 mRNA. <i>Rna</i> , 0, , rna.079378.122.	1.6	0

#	ARTICLE	IF	CITATIONS
1090	Exploiting pivotal mechanisms behind the senescence-like cell cycle arrest in cancer. <i>Advances in Protein Chemistry and Structural Biology</i> , 2023, , 1-19.	1.0	3
1091	Genomic instability caused by Arp2/3 complex inactivation results in micronucleus biogenesis and cellular senescence. <i>PLoS Genetics</i> , 2023, 19, e1010045.	1.5	13
1092	Regulation of the p53-mediated ferroptosis signaling pathway in cerebral ischemia stroke (Review). <i>Experimental and Therapeutic Medicine</i> , 2023, 25, .	0.8	4
1093	Mechanisms driving the immunoregulatory function of cancer cells. <i>Nature Reviews Cancer</i> , 2023, 23, 193-215.	12.8	40
1094	A ferroptosis-related prognostic model with excellent clinical performance based on the exploration of the mechanism of oral squamous cell carcinoma progression. <i>Scientific Reports</i> , 2023, 13, .	1.6	2
1095	Crosstalk between PML and p53 in response to TGF- β 1: A new mechanism of cardiac fibroblast activation. <i>International Journal of Biological Sciences</i> , 2023, 19, 994-1006.	2.6	1
1096	Hepatocellular carcinoma: molecular mechanism, targeted therapy, and biomarkers. <i>Cancer and Metastasis Reviews</i> , 2023, 42, 629-652.	2.7	13
1097	Identification of an energy metabolism-related six-gene signature for distinguishing and forecasting the prognosis of low-grade gliomas. <i>Annals of Translational Medicine</i> , 2023, 11, 146-146.	0.7	1
1098	Chromosomal Instability as Enabling Feature and Central Hallmark of Breast Cancer. <i>Breast Cancer: Targets and Therapy</i> , 0, Volume 15, 189-211.	1.0	0
1099	Small-molecule correctors and stabilizers to target p53. <i>Trends in Pharmacological Sciences</i> , 2023, 44, 274-289.	4.0	5
1100	Exosomes released from U87 glioma cells treated with curcumin and/or temozolomide produce apoptosis in naive U87 cells. <i>Pathology Research and Practice</i> , 2023, 245, 154427.	1.0	6
1101	Stress granules dynamics and promising functions in pancreatic cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2023, 1878, 188885.	3.3	0
1102	Acquired resistance mechanisms to osimertinib: The constant battle. <i>Cancer Treatment Reviews</i> , 2023, 116, 102557.	3.4	1
1103	Branching out in different directions: Emerging cellular functions for the Arp2/3 complex and WASP-family actin nucleation factors. <i>European Journal of Cell Biology</i> , 2023, 102, 151301.	1.6	7
1104	Li-Fraumeni Syndrome-Associated Dimer-Forming Mutant p53 Promotes Transactivation-Independent Mitochondrial Cell Death. <i>Cancer Discovery</i> , 2023, 13, 1250-1273.	7.7	3
1105	Individualized prognosis stratification in muscle invasive bladder cancer: A pairwise TP53-derived transcriptome signature. <i>Translational Oncology</i> , 2023, 29, 101629.	1.7	2
1106	<sc>TP53</sc> signal pathway confers potential therapy target in acute myeloid leukemia. <i>European Journal of Haematology</i> , 2023, 110, 480-489.	1.1	0
1107	The impact of TP53 and PTEN tumor suppressor genes on response to different breast cancer treatment modalities. , 2022, 13, 105-117.	0.0	0

#	ARTICLE	IF	CITATIONS
1108	P-TEFb promotes cell survival upon p53 activation by suppressing intrinsic apoptosis pathway. <i>Nucleic Acids Research</i> , 2023, 51, 1687-1706.	6.5	5
1109	Could senescence phenotypes strike the balance to promote tumor dormancy?. <i>Cancer and Metastasis Reviews</i> , 2023, 42, 143-160.	2.7	2
1110	Sellar B lymphoblastic lymphoma mimics pituitary apoplexy with newly discovered gene mutations in TP53 and PAX5: A case report. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	1
1111	p53 promotes peroxisomal fatty acid β -oxidation to repress purine biosynthesis and mediate tumor suppression. <i>Cell Death and Disease</i> , 2023, 14, .	2.7	5
1112	UFL1, a UFMylation E3 ligase, plays a crucial role in multiple cellular stress responses. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	4
1113	Comprehensive analysis of the correlation of the pan-cancer gene HAUS5 with prognosis and immune infiltration in liver cancer. <i>Scientific Reports</i> , 2023, 13, .	1.6	1
1114	Hallmarks and Biomarkers of Skin Senescence: An Updated Review of Skin Senotherapeutics. <i>Antioxidants</i> , 2023, 12, 444.	2.2	9
1115	Gold-containing liposomes and glucose-coated gold nanoparticles enhances the radiosensitivity of B16F0 melanoma cells via increasing apoptosis and ROS production. <i>Life Sciences</i> , 2023, 318, 121495.	2.0	6
1116	Multiple low-dose radiation-induced neuronal cysteine transporter expression and oxidative stress are rescued by N-acetylcysteine in neuronal SH-SY5Y cells. <i>NeuroToxicology</i> , 2023, 95, 205-217.	1.4	2
1117	Effects of Ginsenoside Rg1 on the Biological Behavior of Human Amnion-Derived Mesenchymal Stem/Stromal Cells (hAD-MSCs). <i>Stem Cells International</i> , 2023, 2023, 1-19.	1.2	0
1118	Molecular Drivers of Myelodysplastic Neoplasms (MDS)â€”Classification and Prognostic Relevance. <i>Cells</i> , 2023, 12, 627.	1.8	2
1119	Elephant TP53-RETROGENE 9 induces transcription-independent apoptosis at the mitochondria. <i>Cell Death Discovery</i> , 2023, 9, .	2.0	1
1120	DNAzyme-Powered DNA Walker for Cooperative Expression Imaging of Mutant p53 and Telomerase in Cancer Cells. <i>Analytical Chemistry</i> , 2023, 95, 4122-4130.	3.2	8
1121	Prognostic Significance of Iron Metabolism Related Genes in Human Lung Adenocarcinoma. <i>Cancer Management and Research</i> , 0, Volume 15, 203-216.	0.9	1
1122	Metastatic colorectal cancer: mechanisms and emerging therapeutics. <i>Trends in Pharmacological Sciences</i> , 2023, 44, 222-236.	4.0	30
1123	P53 Gene Expression and Nitric Oxide Levels after Artemisinin-Caffeine Treatment in Breast, Lungs and Liver of DMBA-Induced Tumorigenesis. <i>Asian Pacific Journal of Cancer Prevention</i> , 2023, 24, 451-458.	0.5	1
1124	Tumor Suppressor Genes. , 2023, , 97-120.		0
1125	ISG20L1 acts as a co-activator of DAPK1 in the activation of the p53-dependent cell death pathway. <i>Journal of Cell Science</i> , 2023, 136, .	1.2	2

#	ARTICLE	IF	CITATIONS
1126	Targeting p53 pathways: mechanisms, structures, and advances in therapy. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	62
1127	An Activatable NIR Fluorescent Probe for NAD(P)H and Its Application to the Real-Time Monitoring of p53 Abnormalities In Vivo. <i>Angewandte Chemie</i> , 2023, 135, .	1.6	1
1128	An Activatable NIR Fluorescent Probe for NAD(P)H and Its Application to the Real-Time Monitoring of p53 Abnormalities In Vivo. <i>Angewandte Chemie - International Edition</i> , 2023, 62, .	7.2	17
1129	p53 Function and Dysfunction in Human Health and Diseases. <i>Biomolecules</i> , 2023, 13, 506.	1.8	3
1130	<i>MDM2</i> for the practicing pathologist: a primer. <i>Journal of Clinical Pathology</i> , 2023, 76, 285-290.	1.0	0
1131	P53 Deficiency Accelerate Esophageal Epithelium Intestinal Metaplasia Malignancy. <i>Biomedicines</i> , 2023, 11, 882.	1.4	1
1132	Emerging Therapeutic Approaches to Target the Dark Side of Senescent Cells: New Hopes to Treat Aging as a Disease and to Delay Age-Related Pathologies. <i>Cells</i> , 2023, 12, 915.	1.8	6
1133	DTX3L E3 ligase targets p53 for degradation at poly ADP-ribose polymerase-associated DNA damage sites. <i>IScience</i> , 2023, 26, 106444.	1.9	4
1134	Ze-Qi decoction inhibits non-small cell lung cancer growth and metastasis by modulating the PI3K/Akt/p53 signaling pathway. <i>Journal of Traditional and Complementary Medicine</i> , 2023, 13, 417-429.	1.5	1
1135	Dihydroorotate dehydrogenase regulates ferroptosis in neurons after spinal cord injury via the p53-ALOX15 signaling pathway. <i>CNS Neuroscience and Therapeutics</i> , 2023, 29, 1923-1939.	1.9	8
1136	Reduced Levels of Misfolded and Aggregated Mutant p53 by Proteostatic Activation. <i>Cells</i> , 2023, 12, 960.	1.8	0
1137	The RNA binding protein RALY suppresses p53 activity and promotes lung tumorigenesis. <i>Cell Reports</i> , 2023, 42, 112288.	2.9	1
1138	Identifying prognostic gene panels in acute myeloid leukemia. <i>Expert Review of Hematology</i> , 2023, 16, 277-287.	1.0	1
1139	Centipeda minima active components and mechanisms in lung cancer. <i>BMC Complementary Medicine and Therapies</i> , 2023, 23, .	1.2	1
1141	The expression level of ARF and p53 in AML patients, and their relation to patients' outcome. <i>Egyptian Journal of Medical Human Genetics</i> , 2023, 24, .	0.5	0
1142	Roles of p53-Mediated Host-Virus Interaction in Coronavirus Infection. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6371.	1.8	4
1143	Tumor-Suppressive Functions of the Aryl Hydrocarbon Receptor (AhR) and AhR as a Therapeutic Target in Cancer. <i>Biology</i> , 2023, 12, 526.	1.3	6
1144	Murine herpesvirus-68-related growth factors treatment correlates with decrease of p53 and HIF-1 protein levels. <i>Pathogens and Disease</i> , 2023, 81, .	0.8	0

#	ARTICLE	IF	CITATIONS
1145	Circulating Cell-Free Nucleic Acids as Biomarkers for Diagnosis and Prognosis of Pancreatic Cancer. <i>Biomedicines</i> , 2023, 11, 1069.	1.4	1
1146	Somatic alterations of TP53 and MDM2 associated with response to enfortumab vedotin in patients with advanced urothelial cancer. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	1
1147	Targeting USP2 regulation of VPRBP-mediated degradation of p53 and PD-L1 for cancer therapy. <i>Nature Communications</i> , 2023, 14, .	5.8	7
1148	Determination of Key Components in the <i>Bombyx mori</i> p53 Apoptosis Regulation Network Using Y2H-Seq. <i>Insects</i> , 2023, 14, 362.	1.0	0
1149	PRIMA-1 inhibits Y220C p53 amyloid aggregation and synergizes with cisplatin in hepatocellular carcinoma. <i>Frontiers in Molecular Biosciences</i> , 0, 10, .	1.6	2
1150	Cell cycle arrest: A breakthrough in the supportive care of older cancer patients. <i>Journal of the American Geriatrics Society</i> , 2023, 71, 2297-2307.	1.3	2
1151	Loss of p53 enhances the tumor-initiating potential and drug resistance of clonogenic multiple myeloma cells. <i>Blood Advances</i> , 2023, 7, 3551-3560.	2.5	1
1152	The Multifaceted Role of Annexin A1 in Viral Infections. <i>Cells</i> , 2023, 12, 1131.	1.8	1
1153	Pleiotropic role of TRAF7 in skull-base meningiomas and congenital heart disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2023, 120, .	3.3	4
1154	Proteomics mining of cancer hallmarks on a single-cell resolution. <i>Mass Spectrometry Reviews</i> , 0, , .	2.8	0
1155	Genetically Encoded DNA Origami for Gene Therapy In Vivo. <i>Journal of the American Chemical Society</i> , 2023, 145, 9343-9353.	6.6	16
1157	Tumor Suppressor Genes and Cell Fate Control. , 2023, , 435-443.		0
1158	Biomarkers of aging. <i>Science China Life Sciences</i> , 2023, 66, 893-1066.	2.3	60
1159	Integrated transcriptome landscape of ALS identifies genome instability linked to TDP-43 pathology. <i>Nature Communications</i> , 2023, 14, .	5.8	8
1160	Genome-wide screen for anticancer drug resistance in haploid human embryonic stem cells. <i>Cell Proliferation</i> , 2023, 56, .	2.4	0
1163	ROS-Responsive Nanoparticle Delivery of mRNA and Photosensitizer for Combinatorial Cancer Therapy. <i>Nano Letters</i> , 2023, 23, 3661-3668.	4.5	8
1167	Role of the gut microbiota in anticancer therapy: from molecular mechanisms to clinical applications. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	27
1210	Pathogenesis of cancers derived from thyroid follicular cells. <i>Nature Reviews Cancer</i> , 2023, 23, 631-650.	12.8	6

#	ARTICLE	IF	CITATIONS
1232	Molecular Mechanisms of Environmental Oncogenesis. , 2023, , 3-60.		0
1247	The roles of ubiquitination in AML. Annals of Hematology, 0, , .	0.8	0
1251	Solanum nigrum Linn.: Advances in anti-cancer activity and mechanism in digestive system tumors. , 2023, 40, .		2
1255	Deer antlers: the fastest growing tissue with least cancer occurrence. Cell Death and Differentiation, 2023, 30, 2452-2461.	5.0	1
1271	An Explainable Model to Support the Decision About the Therapy Protocol for AML. Lecture Notes in Computer Science, 2023, , 431-446.	1.0	0
1276	Permission to pass: on the role of p53 as a gatekeeper for aneuploidy. Chromosome Research, 2023, 31, .	1.0	2
1278	Molecular mechanisms in colitis-associated colorectal cancer. Oncogenesis, 2023, 12, .	2.1	3
1282	Mechanisms of ferroptosis and targeted therapeutic approaches in lymphoma. Cell Death and Disease, 2023, 14, .	2.7	0
1302	Epigenetic Alterations in Pancreatic Cancer. Epigenetics and Human Health, 2023, , 275-294.	0.2	0
1305	P53, ROS: Redox Regulation Signaling, Metabolic Reprogramming, and Autophagy in Cancer. , 2023, , 237-268.		0
1330	Cellular senescence of renal tubular epithelial cells in acute kidney injury. Cell Death Discovery, 2024, 10, .	2.0	1
1344	Tumorsuppressorgene. , 2024, , 115-141.		0